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 Abstract 
 
Asthma and chronic obstructive pulmonary disease (COPD) are associated 
with periods of worsened symptoms, known as exacerbations. Severe exac-
erbations can result in hospitalisation, irreversible decline of the disease 
and sometimes death. Thus, exacerbations are a major cause of morbidity, 
mortality and healthcare cost. Treatment or prevention of exacerbations is 
an area of unmet medical need as the current standard of care has insuffi-
cient impact on exacerbation frequency and severity. 
Respiratory viral infections are hypothesized to be important triggers of 
exacerbations. It has been shown that 41-95% of asthma exacerbations and 
22-57% of COPD exacerbations are associated with a respiratory virus in-
fection, the most common agent being human rhinovirus (RV). Other vi-
ruses frequently associated with exacerbations include respiratory syncytial 
virus and influenza. Prevention or attenuation of respiratory virus infec-
tions could therefore have significant impact on exacerbation frequency 
and severity. 
The mechanisms by which viruses trigger exacerbations are poorly un-
derstood, although there is evidence for defective anti-viral interferon 
(IFN) responses in cells from patients with asthma and COPD. Further in-
vestigation of host-virus interactions and their impact on underlying airway 
disease, may lead to novel therapeutic targets for the prevention of exacer-
bations.  
We investigated host-virus interactions in asthma and COPD through a 
multi-faceted approach. First, we performed an in vitro functional ge-
nomics screen using RNA interference (RNAi), to identify targets that are 
essential for RV replication in primary normal human bronchial epithelial 
cells. Second, we evaluated the efficacy of inhaled IFNβ-1a for the preven-
tion of severe asthma exacerbations in a Phase 2 trial. Finally, we per-
formed an observational, longitudinal study in COPD patients to 
investigate the relationship between exacerbations, viral and bacterial in-
fections, air pollution and anti-microbial peptides (AMPs). 
In the first study, we identified lanosterol synthase (LSS) as a potential 
therapeutic target which, when inhibited, blocks RV replication and en-
hances the RV-induced IFNβ response. We discovered that the mechanism 
 of this effect was related to the induction of a regulatory sterol, 24(S),25 
epoxycholesterol.  
In our phase 2 trial (INEXAS), we found that inhaled IFNβ-1a did not 
prevent the occurrence of severe asthma exacerbations, but improved peak 
expiratory flow (PEF). In an exploratory analysis, we also identified poten-
tial responder subgroups, based on blood eosinophil counts or serum inter-
leukin (IL)-18 levels.  
In our COPD cohort, we found that both viral infections and increases 
in ambient air pollution were associated with exacerbations. Viral exacer-
bations were strongly associated with upregulation of the IFN response bi-
omarkers, CXCL10, CXCL11 and IFNγ. We went on to discover that the 
levels of beta-defensin 2 (hBD-2), an AMP expressed by the lung epithe-
lium, is reduced in the sputum of patients who experienced exacerbations, 
and further found an association between low hBD-2 levels at exacerbation 
and the presence of a respiratory virus.  
The studies presented in this thesis have identified and evaluated key 
components of host-virus interactions and applied those to the context of 
asthma and COPD. In all cases, we found the IFN response to be central, 
not only to the events that occur inside the virus-infected cell, but also to 
the downstream consequences of infection at the tissue and organ level, 
likely playing a key role in both anti-bacterial and anti-viral host defense. 
Despite the extraordinary complexity of the interaction between the virus 
and its host, this thesis demonstrates that key drivers of this interplay can 
be identified, manipulated and, hopefully, developed into future medicines 
for the prevention of asthma and COPD exacerbations. 
Keywords 
Asthma, COPD, exacerbation, virus, interferon 
 Sammanfattning på svenska 
Hundratals miljoner människor världen över lider av kronisk lungsjukdom 
så som astma och kronisk obstruktiv lungsjukdom (KOL). Vid både astma 
och KOL förekommer episoder då man blir försämrad i sin sjukdom, så 
kallade exacerbationer. Allvarliga exacerbationer leder oftast till sjukvårds-
vistelse, försämrad lungfunktion och kan i värsta fall leda till döden. Detta 
innebär ett lidande för individen och är också mycket kostsamt för sjukvår-
den och samhället. Dessvärre fungerar inte dagens astma och KOL-
läkemedel särskilt bra vid just försämrings-episoder. Därför behövs det för-
bättrad behandling samt förebyggande åtgärder för att minska både fre-
kvensen av exacerbationer och dess svårighetsgrad.  
Förkylningsvirus ligger bakom de flesta allvarliga försämringar hos indivi-
der med astma och KOL och det kan rent av vara farligt att bli förkyld vid 
astma och KOL-sjukdom. Studier har visat att 41-95% av astma och 22-
57% av KOL exacerbationer är förknippade med luftvägsvirus.  Rhinovirus 
är det vanligaste förekommande förkylningsviruset och det virus som oftast 
förorsakar försämringar vid astmasjukdom hos både vuxna och barn. Ex-
acerbationer kan även orsakas av influensavirus och respiratoriskt syncyti-
alvirus (RSV). Att förebygga graden av dessa virusinfektioner är viktiga 
för att minimera antalet exacerbationer samt svårighetsgraden av dessa. 
Virus är de minsta biologiska partiklar som kan infektera levande organ-
ismer. Virus sprids oftast via kroppsvätskor, direkt kontakt eller via luften. 
Virus kan inte förflytta sig av egen kraft utan är beroende av en värdcell för 
att kunna spridas och infektera en levande organism. Hur virus triggar 
igång immunförsvaret i luftvägarna som leder till astmaförsämring och/el-
ler KOL-försämring är i stort sett outforskat. Dock vet man att astmatiker 
och KOL patienter har ett bristfälligt försvar mot virus i luftvägsepitelet. 
Detta beror bland annat på att luftvägsepitelet hos astmatiker och KOL-
patienter producerar lägre nivåer av interferoner (IFN), vilket i sin tur leder 
till ett sämre immunförsvar mot virus och därmed ökad virus mängd. 
I denna avhandling har vi studerat virus-värdcell interaktioner för att få en 
ökad förståelse för vad som sker i luftvägarna hos astmatiker och KOL-
patienter vid virusinfektion. Detta är ett viktigt forskningsområde då en 
ökad förståelse om bakomliggande mekanismer vid virus-triggad astma 
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och KOL-försämring kan leda till läkemedelsutveckling som förhindrar el-
ler bromsar frekvensen exacerbationer och/eller dess svårighetsgrad orsa-
kade av virus. 
I den första studien använde vi oss av en så kallad screening assay för att 
identifiera potentiella målproteiner som är viktiga för tillväxten av rhinovi-
rus (förkylningsvirus) i epitelceller från luftvägarna. I den andra delstudien 
använde vi oss av läkemedelsstudien INEXAS där vi undersökte den pre-
ventiva effekten av inhalerat IFN-β1a vid astma exacerbationer av svår ka-
raktär. Slutligen genomförde vi en observationsstudie över tid som 
inkluderade KOL-patienter. Här undersökte vi sambandet mellan exacer-
bationer, virus och bakterie-infektioner, luftföroreningar samt anti-mikro-
biella peptider. 
I det första arbetet i avhandlingen (paper I) fann vi att enzymet lanosterol-
syntas (LSS) som har betydelse i kolesterolbiosyntesen reglerar tillväxten 
av rhinovirus (förkylningsvirus) i epitelceller från luftvägarna. När vi an-
vände en substans som inhiberar LSS fann vi att tillväxten av virus mins-
kade i epitelcellerna och att det anti-virala proteinet IFN-β ökade.  
I avhandlingens andra arbete (paper II) fann vi att astmatiker som behand-
lades med IFN-β1a inhalationer förbättrade sitt peak expiratory flow (PEF)-
värde. Denna behandling hade dock ingen effekt gällande frekvensen av 
svåra exacerbationer. När vi gick vidare och gjorde en mer explorativ stu-
die fann vi att de astmatiker som svarade bäst på IFN-β1a hade ett högre 
antal eosinofiler i blodet, en vit blodcell som är viktig vid både allergier 
och allergisk astma. Lägre nivåer av proteinet interleukin-18 var också as-
socierat med den astmagrupp som svarade bäst på IFN-β1a behandlingen. 
I avhandlingens sista två delarbeten (paper III och paper IV) där vi an-
vände en KOL-kohort fann vi att både virus infektioner och luftförore-
ningar var förknippade med exacerbationer. Virus-triggade exacerbationer 
var starkt förknippade med ett ökat uttryck av IFN relaterade biomarkörer 
så som CXCL10, CXCL11 och IFN-ɣ. Vi fann också att nivåerna av beta-
defensin 2 (hBD-2), en anti-mikrobiella peptid som uttrycks i lungepitelet, 
var lägre i upphostningsprov från KOL-patienter med tillfällig försämrad 
sjukdom (exacerbationer). Låga nivåer av hBD-2 vid exacerbation visade 
sig dessutom vara förknippade med förekomsten av luftvägsvirus hos dessa 
patienter. 
Sammantaget har våra studier identifierat nyckelkomponenter i virus-värd-
cell interaktioner vid astma och KOL. Vi fann att IFN responser är centrala 
för virus bekämpning och inte är begränsade till värdcellen utan yttrar sig 
också på vävnads- och organ-nivå. Våra data föreslår att IFN responser är 
betydelsefulla även vid ett anti-bakteriellt försvar. Trots den stora kom-
plexiteten av interaktionen mellan virus och dess värdcell demonstrerar 
 denna avhandling att det är möjligt att identifiera nyckelkomponenter som 
driver dessa processer. Förhoppningen är att forskning inom detta område 
leder till utvecklingen av framtida mediciner som förhindrar astma och 
KOL exacerbationer. 
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ABBREVI ATIONS    1 
Abbreviations 
ACQ   Asthma control questionnaire 
AEC   Airway epithelial cell 
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ICAM-1  Intercellular adhesion molecule 1 
ICC   Immunocytochemistry 
IgE   Immunoglobulin E 
IFN   Interferon 
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IKKε   I kappa B kinase epsilon 
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MDA5  Melanoma differentiation-associated protein 5 
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Mx1   Myxoma resistance protein 1 
NHBE  Normal human bronchial epithelial cell 
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TLR   Toll-like receptor 
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1. Introduction 
Asthma and chronic obstructive pulmonary disease (COPD) are chronic lung 
diseases which are a significant burden to patients, society and healthcare sys-
tems. Asthma, which is characterised by reversible airflow limitation and is often 
caused by allergic inflammation, affects more than 300 million children and 
adults worldwide (1). COPD differs clinically from asthma in that the airflow ob-
struction is irreversible and that lung function declines progressively. The hall-
mark phenotypes of COPD are emphysema (destruction of the lung tissue) and 
chronic bronchitis (driven by mucus over-production, bacterial colonisation and 
cough). COPD typically develops later in life and is most commonly caused by 
tobacco smoking, although other exposures such as indoor air pollution can be 
important etiological agents, particularly outside of the western world in coun-
tries such as China (2). At present, around 65 million people in the world are di-
agnosed with moderate to severe COPD and by 2030 this disease is predicted to 
become the 3rd leading cause of death globally (3). 
1.1 Exacerbations of asthma and COPD 
Both asthma and COPD are associated with periods of acute disease worsening 
known as exacerbations (in the case of asthma, these are commonly known as 
asthma attacks). Exacerbations can be triggered by a number of extrinsic or in-
trinsic factors, either alone or in combination. For example, asthma exacerba-
tions can be triggered by exposure to the aeroallergen to which the individual is 
sensitised. Other factors which can cause exacerbations of both asthma and 
COPD are air pollution, exercise or stress. However, by far the most common 
triggers of exacerbations are acute respiratory viral infections, as will be de-
scribed in section 1.2 below. Exacerbations are characterized by a worsening of 
lung function and an increase in lung inflammation. Severe exacerbations can 
lead to hospitalisation and in their most severe form can be fatal. In COPD, pa-
tients fail to completely recover the loss of lung function which occurs during an 
exacerbation, thus causing a downward spiral in the progression of the disease 
(4). In some patients, exacerbations can be frequent events, occurring 2 or more 
times per year (5). Such patients are often referred to as “frequent exacerbators”. 
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It is these patients who carry the highest disease and healthcare burden. Unfortu-
nately, despite the combinations of inhaled bronchodilators and anti-inflamma-
tory corticosteroids which are the standard-of-care therapies for asthma and 
COPD, exacerbations remain a problem. Thus, there is significant unmet need for 
therapies which prevent exacerbations, and this is currently a major focus of 
drug discovery and development. 
 
1.2 The role of viruses in asthma  
and COPD exacerbations 
Respiratory viral infections are believed to be the most important and common 
triggers of asthma and COPD exacerbations. In the case of asthma, this had been 
contended for decades (6-8), but it was not until the emergence of molecular vi-
rology methods in the 1990s that the prevalence of viral infections at exacerba-
tion was fully appreciated (9). Using PCR detection methods, it has been shown 
that 41-95% of asthma exacerbations and 22-57% of COPD exacerbations are 
associated with a respiratory virus infection, the most common agent being hu-
man rhinovirus (RV) (10, 11). Other viruses frequently associated with exacer-
bations include respiratory syncytial virus (RSV) and influenza (10, 11). Using 
sophisticated electronic methods to capture daily patient-reported colds and 
lower respiratory tract symptoms in COPD patients, coupled with molecular de-
tection of viruses, a recent study has suggested that the prevalence of viral exac-
erbations may be even greater than suggested by molecular detection methods 
alone (12).  
Another body of evidence supporting the role of viral infections in exacerba-
tions comes from seasonal epidemiology. Seasonal peaks of exacerbations occur 
contemporaneously with periods of increased risk of infection. For example, the 
so-called “September peak” of asthma exacerbations in school-age children and 
younger adults coincides with a peak of RV infections following the post-sum-
mer return to school (13-20). In older adults, asthma and COPD exacerbations 
peak during the Christmas week, a time when families get together, enhancing 
the spread of viruses such as influenza (14, 21, 22). 
Whilst the molecular detection of viruses and the seasonal epidemiology 
show an association between viral infections and exacerbations, they provide no 
indication of causality. However, a significant step towards demonstrating that 
viruses can actually trigger exacerbations was made by the establishment of ex-
perimental RV challenge models in asthma and COPD patients. Such models 
have demonstrated that inoculation of a small dose of RV into the nose gives rise 
to lower airway changes consistent with the occurrence of an exacerbation (8, 
23-27).  
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Given the above evidence, preventing or attenuating respiratory viral infec-
tions poses a substantial opportunity for the prevention of asthma and COPD ex-
acerbations. Moreover, exacerbations associated with viral infections are often 
more severe and longer in duration than non-viral exacerbations (28). Prevention 
or attenuation of respiratory virus infections therefore could have significant im-
pact on the burden and progression of asthma and COPD. 
1.3 Human rhinovirus (RV) 
RV is a respiratory pathogen which circulates year-round and is associated with 
approximately 50% of episodes of the common cold (29). RV is the virus most 
commonly detected during exacerbations, typically making up around half to 
two-thirds of virus positive exacerbations (10, 11). As such, RV deserves particu-
lar attention and is consequently one of the most studied viruses in the context of 
asthma and COPD. 
1.3.1 RV structure and virology 
RV, a member of the Picornaviridae family, is a non-enveloped virus consisting 
of a heteromeric protein capsid, containing a single positive strand RNA genome 
(29). Over 160 genotypes - or serotypes - of RV have been identified and these 
are grouped based on sequence identity into species A, B or C and also on entry 
receptor into major (intercellular adhesion molecule-1 (ICAM-1)) and minor 
(low-density lipoprotein receptor (LDLR) or related proteins) groups (30-34). 
The RV-C species utilizes a different entry receptor to the above, which has re-
cently been reported to be cadherin-related family member 3 (CDHR3) (35). The 
RV genome is around 7 kb in length and encodes a single polyprotein which en-
codes the structural proteins, VP1-4, and the non-structural proteins, 2A-2C and 
3A-3D (29) (see Figure 1).  
Figure 1. The RV genome 
The 7 kb RV genome is translated into a single polypeptide which encodes the individual viral pro-
teins. The 5’ untranslated region (UTR) contains the VPg priming protein cap (encoded by 3B) and 
an internal ribosome entry site (IRES). The P1 region encodes the capsid proteins, VP1-VP4. The P2 
and P3 regions encode the non-structural proteins, including viral 2A and 3C proteases, and the 
RNA-dependent RNA polymerase, 3D. The polyprotein is cleaved into the individual proteins by the 
viral proteases, 2A and 3C. At the 3’ end is a poly(A) tail. 
AAAAAnVP4 VP3 VP1 2A 2B 2C 3A 3B 3C 3DVP2
P1 P2 P3
Structural (capsid) proteins Non-structural proteins
ProteaseProtease Polymerase
5’ UTR
IRES
VPgVPg
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 The principal natural host cells of RV are the epithelial cells lining the res-
piratory tract. Initial infection usually occurs in the nasal epithelium and the vi-
rus is thought to spread towards to the lower parts of the respiratory tract via the 
release of progeny virus from infected epithelial cells. Other cell types such as 
peripheral blood mononuclear cells (PBMC), dendritic cells (DC), macrophages 
and T cells can also be infected with RV, although there is limited evidence that 
viral replication occurs in those cells (36-45). 
 Upon binding to its entry receptor on the cell surface, RV enters the cell 
via endocytosis. Uncoating of the viral genome occurs by endosomal acidifica-
tion, and the viral RNA enters the cytoplasm where translation occurs to produce 
the viral polyprotein (Figure 2). A recent study uncovered a novel role for the li-
pid-modifying enzyme, PLA2G16, in the delivery of RV genome to the cyto-
plasm (46). Viral proteases cleave the polyprotein into its individual 
components.  
 
Figure 2. Simplified diagram of the RV replication cycle 
1. An RV particle enters the airway epithelial cell via its entry receptor (ICAM-1, LDLR or CDHR3). 
2. The viral particle then enters the cell via endocytosis. 3. Under low pH, destabilization of the cap-
sid occurs followed by uncoating of the viral +ve stranded RNA genome. 4. The viral genome enters 
the cytoplasm and begins translation of the viral proteins. 5. Replication organelles are formed from 
Golgi apparatus membranes, which facilitate the generation of new viral genomes. 6. Structural pro-
teins assemble to form new viral capsids. 7. Viral genomes are packaged into the newly produced 
capsids, followed by 8. release of progeny virus particles from the cell. Diagram constructed based 
on data in reference (29). 
 Certain non-structural proteins such as 2B, 3A and 3AB, interact with host 
proteins to disrupt internal lipid membranes such as the Golgi apparatus, trans-
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Golgi network and endoplasmic reticulum (ER), hijacking those membranes to 
form viral replication organelles and in so doing, shutting down host protein syn-
thesis and trafficking (47, 48). The RNA-dependent RNA polymerase (3D) as-
sembles on those membranes to facilitate genome replication to produce progeny 
viral genomes.  By a to-date poorly understood process, progeny viral genomes 
are packaged into assembling capsids to form progeny viral particles, which are 
then released from the cell by lysis or other means (Figure 2). A recent report 
from Mousnier et al uncovers a previously unknown, essential role for myristoy-
lation of the VP0 precursor in viral capsid assembly (49). Chen et al have shown 
that RV2 can be released from the cell in a non-lytic manner via phosphatidyl-
serine lipid vesicles (50). A single RV replication cycle takes 8-12 hours, thus 
supporting rapid spread along the respiratory tract. 
1.3.2 RV epidemiology & clinical relevance 
Molecular epidemiology studies have shown that multiple RV serotypes circu-
late at any given time, with no significant over-representation of any particular 
serotype or species (51-55). In addition to the broad number of circulating sero-
types, long-lasting immunity to RV infections is thought to be weak, resulting in 
life-long susceptibility to RV (56, 57). These factors also make designing vaccine 
strategies against RV somewhat challenging.  
 Clinically, all serotypes are believed to be able to cause the common cold 
and it is not known whether any particular species is more likely to cause colds 
than another. However, there are apparent differences between species in the se-
verity of the asthma or COPD symptoms that they cause. For example, RV-C is 
known to be highly pathogenic in younger children and is possibly the most im-
portant driver of paediatric viral wheeze in children from 3 years of age (58, 59). 
When it comes to asthma exacerbations, RV-A and -C have been shown to be 
more pathogenic than RV-B (60). RV infections in early life are suggested to be 
major risk factors for the subsequent development of asthma. In a birth cohort 
study, wheeze associated with RV infection in the first 3 years of life gave a sig-
nificantly increased odds for the development of asthma by age 6 (odds ratio = 
9.8) (61). 
 Given the large number of RV serotypes which can trigger exacerbations, 
any therapeutic approach aimed at targeting RV-induced exacerbations needs to 
be able to target a sufficiently broad spectrum of serotypes.  
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1.4 Innate anti-viral immunity 
1.4.1 The airway epithelium as a barrier to respiratory viruses 
The nasal, tracheal and bronchial epithelium provides the first line of innate im-
mune defense against inhaled irritants, particles and pathogens such as respira-
tory viruses, and is therefore a major determinant of overall host response to 
infection. The airway epithelium is a pseudostratified barrier, with ciliated cells 
and mucus-producing goblet cells lining the surface and an underlying pluripo-
tent basal cell population which provides a continuous regenerative supply (see 
Figure 3) (62, 63).  
 
Figure 3. The airway epithelial barrier. 
The airway epithelium acts as both a physical and a biochemical barrier to infection. Ciliated cells 
and mucus-producing goblet cells form the airway surface. Tight junctions between these cells pre-
vent the invasion of pathogens and other inhaled particles. The airway surface is lined by cilia 
bathed in periciliary liquid. An overlying mucus layer, which traps inhaled particles, is transported 
by the cilia, carrying particles away from the airway. Finally, in response to insult such as an infec-
tion, the cells orchestrate a protective response which includes the release of mediators such as 
IFNs, AMPs and alarmins. 
 The airway epithelial mucosa acts as both a physical and biochemical bar-
rier to infection, possessing several properties which contribute to host defense 
(see Figure 3). First, the epithelial barrier forms tight junctions between neigh-
bouring cells, preventing the penetration of viruses and other particles through 
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the barrier (64, 65). Second, the beating cilia of the ciliated cells and the mucus 
released by the goblet cells act in concert to produce the mucociliary escalator, 
which traps particles and carries them out of the airways via mucociliary clear-
ance. Third, in response to an insult such as a viral infection, airway epithelial 
cells rapidly produce and release certain innate response proteins, such as inter-
ferons (IFNs), anti-microbial peptides (AMPs e.g. beta defensins) and alarmins 
(e.g. interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP)), 
which orchestrate immune responses and protect the surrounding cells and tissue 
from spread of the invading pathogen (66-73). In asthma and COPD, evidence 
has been provided for dysregulation of all of the above features (62, 64, 65, 72).  
 
1.4.2 The type I and III interferon response  
One of the major components of cellular innate anti-viral immunity is the IFN 
response. Upon viral infection with respiratory viruses such as RV, RSV and in-
fluenza, pattern recognition receptors such as toll-like receptor (TLR) 3/7/8, ret-
inoic acid-inducible gene (RIG)-I and melanoma differentiation-associated 
protein (MDA) 5, recognise the viral RNA genome and trigger, via interferon re-
sponse factor (IRF) 3 or IRF7 signalling, the transcription and release of type I 
(IFN and IFNβ) and type III IFNs (IFN1,2,3) (Figure 4) (74-76). The type I 
IFNs, which are produced by the majority of cell types in response to viral infec-
tion, bind to their receptor, IFNAR, on surrounding cells. The type III IFNs, 
which are primarily released by virus-infected epithelial cells, bind to a complex 
of the IL-10 receptor  chain and the IFN1 receptor  chain. In the case of both 
type I and III IFN receptor engagement, a signaling cascade is activated which 
results in the formation of a signal transducer and activator of transcription 
(STAT) 1-STAT2-IRF9 signalling complex (termed the interferon-stimulated 
gene factor (ISGF) 3 complex) (see Figure 4).  
 Signalling in response to type I and III IFNs results in a broad transcrip-
tional response involving several hundred so-called IFN-stimulated genes (ISG) 
(Figure 4) (77). These genes have diverse functions such as prevention of viral 
genome replication (e.g. myxoma resistance protein 1 (Mx1)) and cleaving host 
and viral RNA (oligoadenylate synthetase 1 (OAS1), ribonuclease L (RNase L)), 
inducing a so-called anti-viral state in the responding cell, which serves to limit 
viral spread (74, 78). Other ISGs are released from the cell and serve to activate 
cells of the adaptive immune system, such as CXC motif chemokine ligand 
(CXCL) 10 and CXCL11, which induce migration of T cells via CXC motif 
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chemokine receptor (CXCR) 3 (79). Thus, the type I and III IFN response or-
chestrates a broad innate and adaptive immune response to viral infection. 
 
Figure 4. Type I and III IFN signalling. 
Upon infection with an RNA virus, the viral RNA genome is sensed either in the endosome by TLR3, 
7 or 8, or in the cytoplasm by the helicases RIG-I or MDA5. This leads to the activation of a signal-
ling pathway via tank-binding kinase (TBK)1 and I-kappa B kinase (IKK) ε, leading to the transloca-
tion of the transcription factors IRF3 or IRF7 to the nucleus and expression of the IFNA, IFNB or 
IFNL genes. IFNα, β, and λ are then released from the cell and bind to their respective receptors on 
neighbouring cells. Receptor activation leads to signalling via Janus kinase (JAK) 1 and tyrosine ki-
nase (TYK) 2 to form the ISGF3 signalling complex, which consists of phosphorylated STAT1, 
STAT2 and IRF9. The ISGF3 complex drives the transcription of several hundred ISGs. 
1.4.3 Evidence for defective innate anti-viral immunity 
 in asthma and COPD 
The immune mechanisms by which viral infections can trigger exacerbations re-
main poorly understood. Several studies have demonstrated an impaired type I 
and III IFN response in bronchial epithelial cells (BEC), bronchoavleolar lavage 
cells or PBMC from patients with asthma or COPD (25, 39, 66, 80). However, 
not all studies have confirmed this IFN deficiency (81). In the case of asthma, it 
has recently been suggested that IFN impairment is observed in a subgroup of 
patients with severe, therapy-resistant atopic or neutrophilic asthma, but not in 
patients with well-controlled asthma (82-84). In one study, Spann et al showed 
that IFN impairment in cells from asthmatic patients compared to controls was 
virus-specific, suggesting that disease-related perturbations may occur in host 
pathways that are utilised by some viruses but not others (85). 
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 The precise signaling mechanisms leading to IFN deficiency are not well 
understood. In asthma, there is growing evidence for an inverse relationship be-
tween IFN responses and allergic type 2 inflammation, including immunoglobu-
lin (Ig)E signaling, eosinophilic inflammation and group 2 innate lymphoid cells 
(36, 81, 86-92). The expression of SOCS1 (suppressor of cytokine signaling 1) 
protein, which is an inhibitor of cytokine production including interferons, has 
been shown to be increased in the asthmatic epithelium (93). Another recent 
study identified altered expression of certain microRNA which regulate TLR7 
expression in alveolar macrophages, thus giving rise to deficient type I IFN pro-
duction (41).  Less is known about how IFN responses may be suppressed in 
COPD, although in vitro studies suggest that cigarette smoke exposure sup-
presses IFN responses to RV (79). Furthermore, decreased influenza-induced 
IFN responses in BEC from COPD patients was shown to be linked to increased 
levels of miR-132 and decreased formation of protein kinase R (PKR)-mediated 
anti-viral stress granules (94). 
1.5 Therapeutic interventions for  
viral exacerbations 
1.5.1 Direct anti-virals 
Since the 1970s, extensive efforts have gone into discovering and developing 
anti-viral drugs against RV, initially as a treatment for the common cold but 
more recently for the prevention of asthma exacerbations (29, 95). The most 
well-studied anti-RV mechanisms have been 3C protease inhibitors and viral 
capsid binders, which were demonstrated to have broad coverage across the rhi-
novirus serotypes (although notably, capsid inhibitors do not inhibit RV-C) (96, 
97). The most advanced RV 3C protease inhibitor, rupintrivir, showed a modest 
reduction in cold symptoms in a phase 2 clinical trial (98, 99). No further devel-
opment was reported thereafter.  
RV capsid inhibitors have reached a more advanced stage of clinical develop-
ment. Pleconaril, initially discovered by Sterling Winthrop and subsequently de-
veloped by ViroPharma, was tested as an oral drug in two phase 3 trials for the 
common cold (100). Although the primary endpoint was met, the drug was not 
approved by the Food and Drug Administration because the level of clinical ben-
efit was deemed to be insufficient, there was a drug-drug interaction risk with the 
contraceptive pill, and evidence was found for a rapid emergence of drug-re-
sistant mutations (101, 102). Although intranasal pleconaril was subsequently 
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evaluated by Merck and showed a modest reduction in asthma exacerbation 
rates, no further development has been reported (103). Most recently, vapendavir, 
a capsid inhibitor discovered by Biota, was tested in a phase 2 trial in asthmatics 
reporting cold symptoms (SPIRITUS), but no improvement in asthma control 
was observed (104, 105).  
Although direct anti-viral drugs are available for RSV (Synagis) and influ-
enza (Tamiflu), these are licensed specifically to treat severe infections in at risk 
populations (106, 107). Due to the relatively small proportion of exacerbations 
associated with RSV or influenza infections, they are unlikely to be viable as 
stand-alone therapies for the prevention of exacerbations (10, 11). Annual influ-
enza vaccination programs are available in many countries to prevent complica-
tions in at-risk populations, including asthma and COPD patients, but there is no 
evidence that flu vaccination reduces susceptibility to exacerbations caused by 
viruses other than influenza (108, 109). 
1.5.2 Host-targeted therapies 
Targeting host proteins essential for virus infection has two major benefits over 
targeting viral proteins: first, it is easier to identify common pathways essential 
for a broad(er) spectrum of virus species; second, the barrier to development of 
drug-resistant mutant strains is – at least in principal – higher.  
1.5.2.1 Targeting the major group RV entry receptor, ICAM-1 
ICAM-1 is the entry receptor for the major group of RV, which represents ap-
proximately 90% of RV-A and RV-B serotypes (30). Due to the large number of 
serotypes that utilize this receptor, blocking ICAM-1 is an approach that has re-
ceived some attention for the prevention of RV infections or RV-induced exacer-
bations.  
One approach to this has been to deliver recombinant soluble ICAM-1 
(sICAM-1) to the airway. In four trials of inhaled tremacamra in healthy subjects 
experimentally challenged with RV, cold severity was reduced (110). However, 
pharmacokinetics of the drug were poor and the drug required dosing 6 times 
daily. To-date, no further development has been reported. 
Efforts have also been made to develop ICAM-1 blocking monoclonal anti-
bodies (mAbs). Traub et al. reported the discovery of an anti-human ICAM-1 
mAb, 14C11, which blocked RV infection but spared ICAM-1/lymphocyte func-
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tion-associated antigen 1 (LFA-1) interactions, thus potentially leaving host de-
fense intact (111). However, there are no reports of clinical development of this 
molecule. 
1.5.2.2 Interferon-related therapies 
Perhaps one of the most attractive ways of targeting the host to prevent viral ex-
acerbations is to boost the body’s own innate anti-viral defense mechanism, i.e. 
IFN. Type I IFNs have been explored as therapeutic proteins for several decades, 
first with IFN and more recently with IFN. A number of small clinical trials 
have been performed in asthmatics with recombinant inhaled or intranasal hu-
man IFN, with mixed success and some evidence of poor tolerability (112-118). 
More recently, Synairgen performed a phase 2 trial of inhaled recombinant 
IFN-1a for the preventions of asthma worsening following symptomatic colds 
(119). Although the primary endpoint of asthma control was not met in the over-
all study cohort, in the subgroup of patients with difficult-to-treat asthma, IFN-
1a significantly improved asthma control and lung function. Interestingly, an epi-
demiological study of multiple sclerosis patients showed that the use of systemic 
IFN-1a therapy reduced the odds ratio for hospitalisations due to respiratory ill-
nesses, although the specifics of those illnesses (e.g. viral etiology) were not re-
ported (120). 
Approaches that would boost endogenous IFN production, for example via 
stimulation of TLR3, 7/8 or 9, may also be of interest for the prevention of exac-
erbations. Such agonists have reached early clinical development, although to-
date there are no reports from clinical trials specifically evaluating them for the 
prevention of viral exacerbations (121-126).  
1.5.2.3 Targeting regulators of intracellular lipids hijacked by viruses 
Phospatidylinositol-4-phosphate (PI4P) lipids are a major component of the 
Golgi and ER membranes. PI4 kinases (PI4K) are essential for the formation of 
these lipids. Recent work has shown the PI4KIII isoform to be essential for the 
replication of a wide range of Picornaviruses, including RV (127-129). In fact, 
PI4KIII was shown to be the molecular target of enviroxime, a picornavirus in-
hibitor compound first discovered in the 1970s (130). Selective inhibitors of 
PI4KIII have been shown to prevent the virus-induced disruption of the Golgi 
apparatus and the formation of viral replication organelles which occur early 
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during infection, indicating that PI4KIII plays a non-redundant role in this pro-
cess (47, 131). Importantly, PI4KIII inhibitors have been shown to inhibit repre-
sentatives of the RV-A, -B and -C species (132). Although some PI4KIII 
inhibitors have shown toxicity in preclinical models, this pathway remains inter-
esting as a route to target RV-triggered exacerbations (131, 133). 
1.5.2.4 Anti-inflammatory mechanisms 
One hypothesis is that inhibition of virus-induced inflammation may prevent vi-
ral exacerbations. p38 mitogen-activated protein (MAP) kinase and extracellular 
signal-regulated kinase (ERK) inhibitors have shown inhibitory effects on viral 
replication in vitro, as well as inhibitors of phospatidylinositol-3 kinases (PI3K) 
(134-136). In the case of both p38 MAK kinase and PI3K inhibitors, recent, un-
published clinical trials have reported beneficial effects on COPD exacerbations 
(137, 138). One recent trial addressed the hypothesis that inflammation triggered 
directly by innate viral RNA recognition may be an important driver of exacer-
bations. In this trial, a monoclonal TLR3 blocking antibody was tested in an ex-
perimental RV challenge model but failed to prevent RV-induced worsening of 
asthma symptoms and lung function (139). 
1.5.2.5 Evidence for anti-viral effects of existing therapies 
As mentioned previously, exacerbations remain a problem for many asthma and 
COPD patients, despite current standard-of-care therapies. The mainstay therapy 
for asthma is the combination of an inhaled corticosteroid (ICS) to dampen in-
flammation and an inhaled long-acting B2 receptor agonist (LABA) as a broncho-
dilator (140). For COPD, long-acting muscarinic receptor antagonists are also 
included in the therapy guidelines (141). Whilst these therapies do reduce exacer-
bation frequency, there are limited data on whether they specifically prevent vi-
rus-triggered exacerbations (142, 143). However, Reddel et al showed that 
budesonide (ICS) and formoterol (LABA) therapy reduced the rate of common 
cold-related asthma exacerbations (144). Several in vitro studies have investi-
gated whether corticosteroids and/or LABA directly impair RV replication or 
RV-induced IFN responses. Whilst some studies report no effect on either pa-
rameter, others show impairment of IFN responses with corticosteroids (145-
149). The differences between these studies may reflect differences in protocols 
and/or the specific drug(s) used. 
  
1 .  INTRODUCTION   17 
The macrolide antibiotic, azithromycin, has been reported to induce IFN re-
sponses to in vitro and in vivo RV infection (150-152). Other macrolide analogues 
were subsequently shown to possess increased anti-viral effects compared to 
azithromycin (153). In a 48-week randomized, placebo-controlled trial, oral 
azithromycin significantly reduced the rate of exacerbations in patients with per-
sistent, uncontrolled asthma (154).  
 Omalizumab is an anti-IgE mAb which is licensed for the treatment of pa-
tients with severe asthma (155). The ICATA and PROSE trials demonstrated a 
significant effect of omalizumab in preventing exacerbations in asthmatic chil-
dren during the September peak, and ex vivo experiments in PBMC and 
plasmacytoid (p)DC showed that the clinical benefit in PROSE correlated with 
the level of RV-triggered IFN release (40, 87, 156).  
Interestingly, lebrikizumab, an anti-IL-13 mAb currently under development 
by Genentech, was trialed in severe asthmatics and although it did not show 
promise in terms of reducing overall exacerbation frequency, seasonal exacerba-
tion peaks were suppressed (90, 157).  
The results with omalizumab and lebrikizumab support the pre-clinical find-
ings showing an inverse relationship between type-2 allergic inflammation and 
type I IFN responses. It will be intriguing to determine whether other biological 
therapeutics targeting type-2 allergic inflammation (e.g. anti-IL-4, anti-IL-5 and 
anti-IL-5 receptor mAbs) or the type-2-inducing alarmins that are upstream (e.g. 
anti-TSLP), will show evidence of selectively preventing seasonal or viral exac-
erbations. Pertinent to this, benralizumab, an anti-IL-5 receptor blocking mAb, 
has been shown to consistently reduce exacerbations across all seasons (158). 
Statins, which inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) 
reductase, the key rate-limiting enzyme in the cholesterol biosynthetic pathway, 
are the mainstay therapy for the control of hypercholesterolemia. Since many 
respiratory viruses hijack certain components of lipid biosynthesis and metabo-
lism, it seems reasonable to hypothesise that statins may reduce the risk of viral 
infections. Indeed, statins have been shown to inhibit RSV replication in vitro 
(159-161). Interestingly, epidemiological studies have explored statin use in rela-
tion to asthma and COPD and shown a reduction in asthma hospitalization or 
COPD exacerbations (162, 163). It is unknown whether these findings are due to 
an effect of statins on respiratory viral infections. However, a randomized con-
trolled trial of simvastatin in COPD patients failed to show any benefit on exac-
erbation rates (164). 
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1.6 The relationship between viral and bacterial 
infections in the lung 
1.6.1 Viral infections and susceptibility to  
secondary bacterial infections 
Colonisation of the airways with bacterial pathogens such as non-typeable Hae-
mophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis, is 
common in COPD patients (165, 166). During COPD exacerbations, bacterial 
load in the lung has been shown to increase and recent studies investigating the 
airway microbiome have demonstrated changes in bacterial composition (167). It 
has been suggested that viral infection may down-regulate host defence leading 
to enhanced bacterial proliferation and inflammation. Mallia et al. have recently 
demonstrated that experimental rhinovirus infection is associated with a very 
high rate of bacterial exacerbation in COPD patients (26), whilst George et al. 
showed similar findings in COPD exacerbations associated with naturally occur-
ring RV infections (168). 
1.6.2 Type I interferons and bacterial infections 
A mechanistic explanation for bacterial outgrowth during a viral COPD exacer-
bation could be the induction of the type I IFN response, which could compro-
mise the anti-bacterial immune response (169). Several investigators have 
reported improved survival and improved clearance of secondary bacterial infec-
tion following influenza infection in mice lacking IFNAR or treated with a neu-
tralising antibody to IFNAR1 (170-174). Similar results were observed in mice 
treated with the synthetic TLR3 and RIG-I agonist, poly(I:C), followed by Strep-
tococcus pneumoniae infection (175). Furthermore, influenza-induced type I IFN 
signalling in mice suppresses Th17-mediated protection from secondary Staphy-
lococcous aureus infection (176). However, other studies have shown protective 
effects of type I IFN signalling on bacterial infection and invasion (177, 178). The 
above studies were all performed in mice and evidence in humans is lacking. An 
ongoing clinical trial of inhaled IFN-1a therapy in COPD patients may shed 
some light on this (179). 
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1.6.3 Anti-microbial peptides 
A key component of cellular anti-microbial defence is the production and release 
of so-called anti-microbial peptides (AMPs). These form a family of small pro-
teins which act to destroy invading pathogens, typically by disrupting the lipid 
membrane or envelope. The main families of AMPs include the defensins (alpha 
and beta), cathelicidins (e.g. LL-37) and protegrins (180, 181). Secretory leuko-
protease inhibitor (SLPI), elafin and pentraxin 3 have also been shown to act as 
AMPs (26). 
Human beta defensins (hBD) are cationic AMPs produced primarily by epi-
thelial cells throughout the body (180). They are known to exert anti-bacterial, 
anti-viral and anti-fungal effects. There are four well-characterised beta defensins 
(hBD-1 -4), although several others have been identified in the human genome. 
hBD-1 is constitutively expressed whilst hBD-2, 3 and 4 are inducible. hBD-2 is 
the most highly expressed in the lung epithelium and is thus thought to be the 
most important beta defensin in terms of host defense in the airways (182). In ad-
dition to its anti-microbial activity, some reports have demonstrated that hBD-2 
has a direct role in modulating cells of the innate and adaptive immune systems 
(183-188). As such, hBD-2 plays an important role in lung host defense and acts 
on the interface between the innate and adaptive immune systems.  
Some evidence exists that the production of AMPs is altered in the COPD 
lung. For example, levels of hBD-2 are reduced in the central airways of COPD 
patients (189). There are also reports of a genetic association between hBD-2 
copy number and COPD, although this is controversial (190-192). A recent in 
vitro study demonstrated a synergistic induction of hBD-2 in BEC co-infected 
with RV and Pseudomonas aeruginosa, but the level of induction was suppressed 
in cells from COPD patients (67). In accordance with this, when experimentally 
inoculated with RV, COPD patients expressed lower levels of several AMPs in 
sputum, compared to healthy smoker controls (26). The lungs of COPD patients 
are known to be rich in proteases such as cathepsins and neutrophil elastase (NE) 
which can degrade AMPs, which is one mechanism by which levels of AMPs 
may be reduced in the COPD lung (193).  
 The interaction between viral infections, AMP production and disease sug-
gest that AMPs may be a key component of the susceptibility of COPD patients 
to colonization and outgrowth of pathogenic bacteria. 
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2. Aims 
The overall aim of this thesis is to identify mechanisms of host-virus interactions 
which may ultimately lead to novel therapeutic targets for the prevention of vi-
rus-triggered exacerbations in asthma and COPD. The thesis contains both a pre-
clinical part involving a search for proteins essential for RV replication in vitro, 
and a clinical part involving both a clinical trial in asthmatics and a non-inter-
ventional biomarker study in COPD patients. The specific aims of these studies 
are presented below. 
 
Paper I 
 
• Identify novel targets for inhibition of RV infection in airway epithelial 
cells, by conducting a high throughput, RNA interference (RNAi)-based 
phenotypic screen of RV infection of primary bronchial epithelial cells.  
• Study the most promising hit from the screen further, to confirm specificity 
and investigate molecular mechanisms. 
 
Paper II 
 
• Investigate the efficacy of inhaled IFNβ-1a for the prevention of severe 
asthma exacerbations following cold symptoms.  
• Evaluate patient subgroups based on exploratory biomarkers to identify po-
tential responder sub-populations. 
 
Paper III 
 
• Conduct a 2-year longitudinal observational study in COPD patients to in-
vestigate the importance of different trigger factors on the occurrence and 
phenotype of exacerbations.  
• Determine the relationship of exacerbations with infection status and blood 
and airway biomarkers.   
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Paper IV 
 
• Investigate the relationship between the AMP, hBD-2, and risk of exacerba-
tions in COPD patients. 
• Study how hBD-2 levels associate with viral and bacterial pathogen status 
during stable disease and at the time of exacerbation.  
 
  
3 .  M ETHODS   23 
3. Methods  
3.1 In vitro models of RV infection 
Cell lines such as HeLa OHIO and HeLa H1 are highly susceptible to RV infec-
tion. A rapid, lytic infection occurs in these lines, with profound cytopathic ef-
fect (CPE) observable after a single or very few infection cycles. For this reason, 
HeLa OHIO or H1 cells are the lines of choice for virus propagation and titra-
tion. Ease of culture and a relatively simple readout (CPE) also make HeLa in-
fection assays a useful tool in drug discovery and they are highly amenable to 
performing high throughput screening (194). However, the major limitation of 
performing studies in these cell lines is that the nature of the infection is very 
different to what is observed when infecting airway epithelial cells (AEC), i.e. 
the natural host cell, with RV. Instead of a profoundly lytic infection, the major-
ity of AEC appear to survive multiple rounds of infection, unless they are inocu-
lated with very high multiplicities of infection (MOI). HeLa cells are known to 
produce a weak IFN response compared to AECs, which may in part explain 
their high susceptibility to infection. To study virus-host interactions in HeLa 
cells could therefore potentially lead to findings of limited physiological rele-
vance, unless subsequently confirmed in AEC. For this reason, all work in Paper 
I was performed in primary normal human bronchial epithelial cells (NHBE) 
cells. Whilst an immortalised AEC cell line such as A549 or H292 would have 
been more convenient to use for a high throughput screen, we used the primary 
cells as our starting point because these are more physiologically relevant and 
are closer to the in vivo phenotype. We found that we could establish a high 
throughput RV infection assay in NHBE cells with sufficient robustness and re-
producibility with which to perform an RNAi screen. 
The choice of readout from an RV infection assay depends largely on the 
main purpose of the study. However, irrespective of the main goal, it is essential 
to perform some measure of viral replication. This is because all other readouts 
are dependent on the viral load in the culture. Viral load can be measured in sev-
eral different ways, in either supernatants (shed virus) or in cell lysates (intracel-
lular virus). In NHBE cells, it is usually easier to detect intracellular virus than 
shed virus. RT-PCR is a common method and if one wants to obtain a nominal 
quantification, a viral standard curve can be included and there are even com-
mercially available qRT-PCR-based kits that enable the calculation of plaque-
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forming units (PFU)-equivalents. If it is important to measure the true concentra-
tion of live shed virus (i.e. PFU/ml or tissue culture infectious dose (TCID)50), 
supernatants can be transferred to HeLa cells for a CPE assay and there are also 
commercially available kits for this purpose. Imaging is a useful tool which per-
mits an assessment of what proportion of cells are infected. This can either be 
done by in situ hybridisation (ISH), using probes to detect RV genomic RNA (as 
utilised in Paper I) or replicative strand RNA, or by immunocytochemistry 
(ICC) using antibodies specific to viral double-stranded DNA or certain viral 
proteins (e.g. 2C, 3A (48) or VP2). Quantification of the signal can then be per-
formed using image analysis software such as Definiens, as described in Paper 
I. 
 In terms of measuring the host response to infection, detailed transcriptional 
analysis can be performed using qRT-PCR or RNAseq. Due to the large number 
of ISGs of different functions expressed during the IFN response, whole tran-
scriptome analysis is advantageous if one wants to capture a holistic view of the 
nature and kinetics of the IFN response under different infection conditions. Re-
leased proteins can be measured in culture supernatants using immunoassays 
such as ELISA, AlphaLisa or Mesoscale Discovery (MSD) assays. It should be 
noted that measuring type I and III IFN proteins directly can be challenging, 
since they are produced in relatively small quantities. It is common that the lev-
els of IFN in supernatants post-RV infection can be below the limit of quantifi-
cation of the available immunoassays. A contributory factor is that RV has been 
shown effectively evade IFN responses (195). One solution to this problem is to 
measure one of the IFN response proteins which are released from the cell, e,g, 
CXCL10 or ISG15 (196). An alternative or complementary readout is to measure 
IFN gene transcription by qRT-PCR, as done in Paper I.  On a technical note, 
when performing immunoassays on supernatants, the samples still contain live 
virus and appropriate biosafety precautions must be taken throughout the proce-
dure. Inactivation of the virus by UV treatment can be performed prior to analy-
sis, but this is not advisable since certain proteins can also be affected by UV 
treatment.  
Although NHBE cells are more physiologically relevant and closer to the in 
vivo phenotype than any cell line, when grown in submerged culture they are 
more similar to the basal cells which underlie the differentiated ciliated and gob-
let cells which line the airway surface. It is those terminally differentiated cells 
which usually become exposed to virus in vivo. This is a limitation of the sub-
merged cell NHBE cell model such as that used in the RNAi screen in Paper I. 
To reach the next level of complexity and physiological relevance, it is of im-
portance to study infection of ciliated and goblet cells. This can be done in vitro 
by differentiating NHBE cells at air-liquid interface (ALI; Figure 5, see Paper I, 
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supplemental methods, for further details on how this is performed) (197). ALI 
cultures form all the different epithelial cell types that are observed in the air-
way, have beating cilia, produce mucus and form tight junctions. ALI cultures 
can be inoculated on the apical (air) side and virus replication and cellular re-
sponses measured over several days post-infection. Similar readouts to those de-
scribed above can be utilized. Moreover, the ALI model permits a much more in-
depth study of the epithelial response to infection with readouts of barrier func-
tion (e.g. transepithelial electrical resistance, TEER) and permeability (e.g. using 
fluorescent particles such as FITC-dextran) becoming possible (198, 199). The 
ability to sample both the apical (air) and basolateral (medium) sides of the cul-
ture allows an assessment of the directionality of released proteins such as IFNs, 
AMPs and alarmins. Furthermore, a time course of samples can be taken from 
the apical side without destroying the culture, permitting longer duration studies 
with fewer individual cultures. As with submerged NHBE, ALI cultures can be 
infected readily with RV, and often a more robust infection occurs in ALI. Of 
particular note, the only available in vitro model of RV-C infection is the ALI 
culture, since the entry receptor, CDHR3, is selectively expressed by ciliated 
cells (96, 200). 
Figure 5. Schematic diagram illustrating the generation of air-liquid interface (ALI) cultures of 
airway epithelial cells. 
 
One limitation of the ALI culture model is that it consists only of AEC and 
does not capture the crosstalk which occurs in tissue with other cell types such as 
endothelial cells, fibroblasts and immune cells. Development of co-culture or 
chip-based microfluidics models has been reported (201-203). Furthermore, ex 
vivo lung explant or precision-cut lung slice models of viral infection have been 
described (204-206). Although this would be an attractive next step, these more 
complex models are yet to be explored in the context of the findings of Paper I. 
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3.2 RNAi as a platform for phenotypic screening 
RNAi is a powerful molecular gene silencing tool, first described in the late 
1990s and subsequently established in mammalian cells in 2001 (207, 208). 
Whilst siRNA rapidly became a widely used research tool, efforts also spawned 
in the pharmaceutical and biotech industry to develop RNAi therapeutics. At the 
time of writing this thesis, the very first RNAi therapeutic was approved by the 
FDA (209). RNAi utilizes the RNA-induced silencing complex (RISC) to de-
stroy specific short RNA sequences. Short interfering (si)RNA molecules are 
double-stranded RNAs which are 21-23 nucleotides (nt) in length containing 2 nt 
overhangs at the 3’ end. One strand is complementary to the target mRNA and 
thus the siRNA molecule can be designed to have specificity for any given gene. 
Delivery to the cell can be performed using specific lipid-based transfection 
methods, as described in Paper I, although other methods can be used. Once in 
the cell, the complementary (targeting) strand is incorporated into RISC, which 
uses the targeting strand as a sequence-specific probe for targeting mRNA for 
cleavage by argonaute 2, resulting in the silencing of that specific gene. The effi-
ciency and kinetics of the gene silencing depend on multiple parameters includ-
ing protein half-life, siRNA sequence, transfection efficiency, knock-down 
efficiency and cell type.  
 Whole-genome and druggable-genome siRNA libraries have been produced 
by several commercial suppliers, making this tool highly amenable to pheno-
typic drug target screening. The fact that primary AEC can be transfected effi-
ciently using siRNA led us to choose this method for performing a phenotypic 
screen to identify host targets essential for RV infection. An alternative was to 
screen one of AstraZeneca’s small molecule compound libraries. However, 
many compounds possess either unknown pharmacology or mixed pharmacol-
ogy against several proteins. Whilst compound screens have the advantage that 
they yield chemical starting points for the design of a drug-like molecule, any 
output of a compound screen would require deconvolution to identify the molec-
ular target(s) responsible for the phenotypic effect. The advantage of siRNA is 
that the target is already known from the start, hence choosing this methodology 
for the screen described in Paper I. In order to increase the chances of identify-
ing drugable targets, we chose to use a druggable genome library representing 
approximately 10,500 genes. 
 There are several issues that need to be considered when performing an 
siRNA functional genomics screen, since hit-calling from such screens is known 
to be susceptible to false negatives and false positives (210, 211). First, although 
the individual siRNA molecules in a library have been optimized by the supplier, 
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it should be borne in mind that knock-down efficiency will vary, and low effi-
ciency knock-down may result in a lack of phenotypic effect. Second, sequence 
related off-target effects can occur, leading to potentially spurious findings. 
Third, siRNA delivery can give rise to cytotoxicity, again leading potentially to 
false negative or positive results, depending on the phenotypic response being 
measured. Finally, one common off-target effect comes from the fact that siRNA 
can induce the anti-viral IFN response in a non-sequence specific manner, which 
is a particular concern when performing a viral infection screen. In Paper I, 
these issues were controlled for as much as possible. For example, 3 independent 
siRNA molecules per gene were utilized, the IFN response was assessed using 
control siRNA during the assay development stage, multiple positive and nega-
tive control siRNA were included on each screening plate, and we included a 
stringent cytotoxicity threshold at the data analysis stage. Furthermore, we con-
firmed the effect of the most interesting screening hit, lanosterol synthase (LSS), 
was not a false positive, using pharmacological inhibitors. The details of this can 
be found in Paper I.  
 Since the emergence of RNAi screening, CRISPR-Cas9 technology has 
emerged as a more elegant and precise method for performing functional ge-
nomics screens (212-214). The advantages of CRISPR/-Cas9 over RNAi are that 
it provides the possibility to functionally knock out, knock in or fine-tune the ex-
pression of a given gene permanently. One limitation is that this is currently not 
feasible in primary cells with a short lifespan, such as NHBE cells. 
 
3.3 Human studies 
In paper II-IV, written informed consent was obtained from all subjects and ethi-
cal approval was obtained from the respective ethics committees in the different 
countries and study centres.  
3.3.1 Asthmatic subjects (Paper II) 
Subjects with severe asthma (GINA step 4-5) and a documented history of fre-
quent severe exacerbations were enrolled for the clinical trial described in Paper 
II . The choice of this population was based on previous experience in a phase 2 
trial of inhaled IFN-1a (119). To ensure the enrollment of patients susceptible to 
virus-triggered exacerbations, an additional requirement was that the exacerba-
tions should be reported by the subject to have been triggered by the common 
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cold or flu. A clear limitation of the latter is recall bias, although the exacerba-
tions themselves had to be documented. Of note, using an epidemiological 
method, a subgroup of asthmatics in the West Sweden Asthma Study cohort re-
ported only having exacerbations following colds or flu, whilst another, separate 
group of frequent exacerbators only reported other triggers such as allergen, 
stress and exercise (215-217). This suggests that a specific “virus susceptible” 
subgroup may exist among asthma exacerbators. 
3.3.2 Subjects with COPD (Papers III-IV) 
In Papers III-IV, all subjects were recruited at the Guangzhou Institute for Res-
piratory disease and were residents of a large metropolitan area surrounding 
Guangzhou, one of China’s largest cities. A broad cohort of COPD patients was 
recruited across all disease severities (GOLD 0-4). In addition, a cohort of con-
trol subjects without COPD was recruited. GOLD 0 is a classification of “at risk” 
subjects without a diagnosis of COPD but with certain symptoms and risk fac-
tors, such as a history of heavy smoking. In the more recent reviews of the 
GOLD criteria, GOLD 0 was not included (218). However, this remains an inter-
esting group to study, particularly in light of recent findings in the group of sub-
jects from the SPIROMICS cohort with COPD-like symptoms but preserved 
lung function (219). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glossary 
GINA (Global Initiative for Asthma) is a medical guidelines or-
ganisation which works with public health officials and healthcare 
professionals globally, to reduce asthma prevalence, morbidity and 
mortality. The GINA global strategy for asthma management guide-
lines are updated on an annual basis and are divided into 4 levels 
(GINA 1-4) based on level of asthma severity and disease control. 
More information on these levels can be found in ref 138 and 
www.ginaasthma.org. 
GOLD (Global Initiative for Chronic Obstructive lung Disease) 
is an organization with works with public health officials and 
healthcare professionals around the world to raise awareness of 
chronic obstructive pulmonary disease and to improve its preven-
tion and treatment. The GOLD committee provides COPD manage-
ment guidelines which are reviewed on a regular basis. The current 
treatment guidelines are divided into GOLD levels A-D based on a 
combination of symptoms scores and exacerbation frequency. More 
information on the guidelines can be found in ref 139. 
  
3 .  M ETHODS   29 
3.3.3 Clinical trial to assess an “on-demand” therapeutic  
intervention for viral exacerbations of asthma (Paper II) 
Most exacerbation trials have tested the effect of chronic therapy on rates of ex-
acerbations. Typically, these studies are performed over a 6 to 12-month period 
in order to obtain sufficient numbers of events for statistical power (142, 156, 
157). In Paper II, we utilized a less conventional trial design in order to assess 
the efficacy of therapeutic dosing of the study drug, modelling an “on-demand” 
treatment approach. Briefly, patients were recruited to the clinic and randomized 
to a 14-day treatment of IFNβ-1a or placebo within 48 hours of reporting cold 
symptoms. Further details on the study design can be found in Paper II. 
 There are several advantages of this “on-demand” trial design. One advantage 
is that since the patient was recruited to the clinic at the time of an event, de-
tailed assessments could be made throughout and after the event, and frequent 
sampling could be done for biomarker analysis. Long term exacerbation trials 
rarely involve such a detailed assessment of the exacerbation events. Another ad-
vantage is that the design closely mimics how the drug would be anticipated to 
be used in real-life, with patients starting to take a course of treatment when they 
recognize symptoms of a cold.  
 There are also a number of challenges when it comes to performing such a 
trial design. For example, there are significant operational and logistical issues in 
ensuring a participant gets the first dose of study drug within 48 hours of report-
ing cold symptoms. Randomisation was performed at this time and it was there-
fore not feasible for the patient to have the course of treatment stored at home. 
Another method to assess a therapeutic intervention would be to use an experi-
mental RV challenge model. Although the design used in Paper II has the ad-
vantage that all events were naturally occurring, the experimental challenge 
model allows greater flexibility in time of dosing, for example allowing a com-
parison of prophylactic and therapeutic dosing. However, there are ethical con-
siderations in performing experimental RV challenge in severe asthmatics. 
Although there are data on how many exacerbations are linked to viral infec-
tions (10, 11), it is less clear what proportion of colds leads to asthma exacerba-
tions. This had a significant impact on the ability to accurately predict 
exacerbation event rates. Since only one course of treatment was given per sub-
ject, we relied on reasonable odds that a single cold would lead to an exacerba-
tion. 
As described in the Introduction, seasonal differences in exacerbations can 
occur, and it has been shown that the seasonality of asthma exacerbations in the 
Northern Hemisphere mirrors that of the Southern Hemisphere (14). This trial 
was performed in multiple centres across several continents in both hemispheres, 
in order to capture these geographical differences. 
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In general, exacerbation trials in both asthma and COPD tend to have lower-
than-predicted exacerbation rates based on 12-month history of exacerbations 
(142, 156, 157). This may be in part due to the beneficial effect to the patient of 
being on a trial, e.g. better compliance to standard-of-care medication, better 
sense of wellbeing and ready access to study physicians. Severe exacerbation 
event rates were also low in our on-demand trial, and the above factors may have 
contributed to this. 
3.3.4 Longitudinal exacerbation study in  
COPD patients (Papers III-IV) 
Longitudinal, observational studies have the advantage that the natural history of 
disease can be assessed over time without significant patient interference or in-
tervention. In the case of the study described in Papers III and IV, subjects were 
followed for two years. All subjects visited the clinical annually for assessments 
and sampling (baseline, 12 months and 24 months). A subgroup of the cohort was 
selected for more in depth assessment of daily symptoms using an electronic pa-
tient-reported outcomes (ePRO) device. Using a Blackberry smartphone, 
EXACT-PRO, a COPD symptom questionnaire which can sensitively detect the 
early onset of exacerbation, was administered to subjects in this subgroup on a 
daily basis (220). Previous studies have demonstrated close to 100% compliance 
and exacerbation detection using this ePRO method (22). When signs of exacer-
bation were detected, the subject was recruited to the clinic for assessments and 
sampling. Thus, subjects were assessed on an annual basis during stable disease, 
and at the time of exacerbation, enabling a within-subject comparison of clinical 
parameters and biomarkers at stable disease and exacerbation. One limitation, 
however, is that only 1 clinic visit was made at the time of exacerbation, so it 
was not possible to study the time course of events during exacerbation and at 
recovery. 
The 2-year observation period with annual assessments and sampling afforded 
the ability to assess the stability of different parameters over time. However, it is 
likely that 2 years is not a sufficient length of time to assess disease progression. 
Typically, studies of disease progression, e.g. lung function decline, follow pa-
tients for 3-5 years (4, 221). 
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3.3.5 Sputum sampling 
Sampling of sputum is a relatively non-invasive method to obtain fluid from the 
lining of the upper airways, permitting an assessment of different cell-associated 
and soluble biomarkers. The most abundant cell types in sputum are macro-
phages, lymphocytes, neutrophils and eosinophils (222, 223). There are two pro-
cedures normally used for the sampling of sputum. Induced sputum involves the 
inhalation of sterile saline (e.g. 4% PBS) followed by the subject coughing up 
and spitting out the sputum sample. This procedure is uncomfortable for the sub-
ject and is done with measurement of lung function before and after the saline 
inhalation. The second procedure, expectorate sputum, is non-invasive and in-
volves the subject coughing up and spitting out sputum without any prior saline 
inhalation. For Paper II, only expectorate sputum was obtained to avoid risk to 
patients and any interference with the trial’s efficacy endpoints. For Papers III-
IV, either induced and expectorate sputum was collected, depending on whether 
it was safe to perform the induced sputum procedure. 
Sputum is expectorated into a petri dish which is then placed on ice for rapid 
processing. Processing involves separating the sputum plugs from saliva, weigh-
ing them followed by addition of PBS and centrifugation to separate the cell 
fraction from the sputum supernatant. At this point, a fraction of the supernatant 
(“PBS supernatant”) was stored at -800C for further use. Afterwards, a fraction 
of the remaining sputum was treated with the reducing agent dithiothreitol 
(DTT) (e.g. Sputasol or Sputolysin), in order to break down the sputum plug. A 
small aliquot of this sample was removed for differential cell count and assess-
ment of cell viability using trypan blue. A fraction of the sputum sample was 
also centrifuged onto a cytospin slide for future cell analysis. The remaining 
sample was centrifuged and DTT supernatants collected and stored at -800C for 
further use. DTT may affect the ability to measure certain proteins in sputum su-
pernatant, hence the advantage of collection both untreated (“PBS”) sputum and 
DTT sputum supernatants. For Paper II, the remaining sputum cells were stored 
in RNA lysis buffer for further analysis. Any sample with more than 10% squa-
mous cell contamination and/or less than 75% cell viability, was deemed unsuit-
able for further analysis. 
In Paper II, subjects were recruited at multiple clinical trial centres, few fo 
which were either experienced or equipped to perform sputum processing. In or-
der to obtain sputum samples from those centres, expectorate sputum was col-
lected directly into a tube and frozen immediately at -800C, providing so-called 
“spit and freeze” sputum samples. Although these samples could not be used for 
soluble protein biomarker analysis, they could be put into RNA lysis buffer for 
RNA isolation and RT-PCR for gene expression or pathogen detection. 
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A limitation of sputum collection is that measurements made in sputum do 
not necessarily reflect ongoing biological of pathological processes in the lower 
airway. A further limitation is the potential for contamination from the orophar-
ynx. Sampling of the lower airways, by collection of bronchial lavage or bron-
choalveolar lavage, can be performed via bronchoscopy. However, this is more 
invasive and for ethical reasons is not always feasible, especially in more severe 
disease or during exacerbations. For this reason, bronchial sampling was not per-
formed in the studies described in Papers II-IV. 
 
3.4 Biomarker analysis methods 
3.4.1 Pathogen detection 
In Papers II-IV, detection of a panel of respiratory viruses was performed in na-
sal lavage or sputum samples using RT-PCR (see individual papers for the de-
tails). In Papers III-IV, a small number of pathogenic bacterial species were 
included in the RT-PCR panel. Furthermore, traditional bacterial culture meth-
ods were used for the detection of a larger range of pathogenic bacterial species 
in sputum.  
It was noted in the analysis for Paper II that virus detection rates were higher 
in sputum than in nasal lavage (see section 4.2). Although it is not clear whether 
this is due to the infection having cleared from the nose and spread to the lung at 
the time of sampling or, alternatively, due to differences in sample quality be-
tween nasal lavage and sputum, this phenomenon has been noted previously 
((22) and Synairgen, personal communication). 
3.4.2 Host response and inflammatory biomarkers 
In Papers II-IV, a range of soluble markers were measured in sputum and/or se-
rum in order to assess lung and systemic inflammatory cytokines, IFN-related 
markers and AMPs. These assays were performed using either ELISA or MSD 
immunoassays. As noted in section 3.1, many IFNs and also inflammatory bi-
omarkers are expressed at levels which are too low for most immunoassays to 
quantify. This is especially the case for the type I IFNs. For example, of >500 
sputum samples measured in the COPD study used in Paper III-IV, IFN was 
detected by MSD assay in only 38 samples (not shown). Several of the samples 
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with failed IFN detection were exacerbations in which a respiratory virus had 
been detected. Even in a previous trial of inhaled IFN-1a, IFN could not be de-
tected in serum by ELISA at any time point post-treatment (Synairgen, personal 
communication).  
For the above reason, assessment of the IFN response in clinical samples 
such as sputum and serum are best performed using IFN response biomarkers 
such as CXCL10, CXCL11 and ISG15. This was the reason for choosing such bi-
omarkers in Paper II and Paper IV. 
mRNA biomarkers can be measured by qRT-PCR or RNAseq in the sputum 
cell fraction. In Paper II, a panel of 5 ISGs was measured by qRT-PCR in either 
sputum cells or “spit and freeze” sputum, to assess the activation of the IFN re-
sponse by inhaled IFN-1a. 
3.5 Statistical methods 
All statistical analyses reported in Papers I-IV were performed using either 
GraphPad Prism, R or Spotfire software. Non-parametric or parametric analysis 
was used as appropriate depending on whether or not the parameter was nor-
mally distributed. A p-value of less than 0.05 was regarded as statistically signifi-
cant. Where multiple comparisons were involved, adjustment for multiple testing 
was performed. Full details of the individual statistical analyses performed are 
described in Papers I-IV. 
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4. Results and Discussion 
The main findings of Papers I-IV are summarized in this chapter. Unpublished 
results of relevance to the findings are also included.  
 
4.1 Lanosterol synthase is a regulator of rhinovi-
rus infection in primary NHBE cells (Paper I) 
The initial aim of the research which led to Paper I was to perform a phenotypic 
screen using RNAi, identify novel targets that inhibit viral replication. The ambi-
tion was that confirmed hits could be taken forward for the development of new 
therapeutics for the prevention of virus-triggered exacerbations. The original 
screening cascade included both RV and RSV. Given the fact that RV and RSV 
are highly unrelated, our rationale was that if we can identify targets that apply 
to both RV and RSV, they are likely to be relevant to a broad spectrum of respir-
atory viruses.  
For the primary screen of the entire drugable-genome siRNA library, we 
chose RV since it is the most common virus type associated with exacerbations. 
However, the choice of RV2, a representative of the minor group of RV, was 
made for pragmatic reasons. Minor group serotypes are members of the RV-A 
species and are defined based on the entry receptor, LDLR and related proteins. 
The minor group makes up less than 10% of RV serotypes. The preference would 
have been to use a representative of the major group since this represents around 
90% of RV-A and B serotypes (note that RV-C would not have been feasible for 
this screen since it only infects differentiated AEC grown at ALI). However, dur-
ing the assay development and optimization stage, of the 6 serotypes evaluated 
(RV2, 10, 14, 16, 22 and 41), RV2 provided by far the best and most robust high-
throughput assay. 
 The original siRNA screening cascade is illustrated in Figure 6. At Pass 3/4 
(technical and biological validation), we intended to include infection assays for 
two additional viruses, RV16 (major group) and RSV. However, the results were 
disappointing. First, we were unable to establish a sufficiently robust medium-
throughput RV16 infection assay in NHBE cells which would permit the testing 
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of the 25 genes which were selected after Pass 2. We therefore decided not to in-
clude the RV16 assay. Although we did succeed in developing a suitable RSV in-
fection assay, only three of the “high-confidence” hits, DNAJC3, EEF1G and 
ZNF614, inhibited RSV. We chose not to follow up on these because at the time 
there were limited or no tools for further target validation and, in the case of 
ZNF614, very little knowledge of its function. However, DNAJC3 is of particular 
interest due to the fact that there are reports of a role in coxsackievirus 3B infec-
tion (another Picornavirus), suggesting that it is involved in the infection of sev-
eral viral species (224). 
 
Figure 6. The siRNA screening cascade. 
Several RNAi-based phenotypic screens for virus replication have been re-
ported in the literature ((210, 211, 225). In general, very few common genes have 
emerged from those screens, even in cases where the same virus was used. This 
highlights the limitations described above around false positives and negatives, 
and also perhaps indicates the impact of different cell types, model systems and 
protocol on the eventual outcome. In spite of these potential concerns, we identi-
fied several hits that have previously been shown to be involved in viral replica-
tion (e.g. oxysterol binding protein (OSBP) genes, DNAJC3, GTF3C2, NR1H3), 
making us confident in the validity of our screening output (47, 224, 226-230).  
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 Following the conclusion of the siRNA screening cascade, we chose to focus 
our efforts on LSS due to the availability of selective small molecule inhibitors 
which would allow us to rapidly confirm the specify of the siRNA results. We 
proceeded to confirm that pharmacological inhibition of LSS inhibits RV repli-
cation. The results of those experiments were promising but left us with a conun-
drum: the anti-viral potencies of all three LSS inhibitors tested were 5-10-fold 
higher than their potencies in an assay of LSS enzymatic activity. From such a 
finding, one would normally conclude this would be the result of some off-target 
effect of the compound. However, two things led us to believe that something 
else might be the reason. First, the same phenomenon occurred with all three 
compounds, which are from different chemical series. Second, the compounds 
were all clinical candidates and had thus gone through rigorous testing for selec-
tivity (231, 232). 
 Rowe et al had shown previously that partial inhibition of LSS in murine 
macrophages, gives rise to an increase in 24(S),25 epoxycholesterol (EC) (233). 
This gave a potential biological explanation for the high anti-viral potency of the 
LSS inhibitors. Accordingly, when we measured 24(S),25 EC in our RV2 infec-
tion assay, we confirmed that low concentrations of LSS inhibitor were associ-
ated with an increase in 24(S),25 EC levels. Intriguingly, the EC50 for 24(S),25 
EC induction was remarkably close to the antiviral EC50. As described in Paper 
I, we subsequently confirmed that exogenous 24(S),25 EC had an anti-viral effect 
in its own right. We first thought that the mechanism for this anti-viral effect 
might be due to activation of the liver X receptor (LXR), since 24(S),25 EC is a 
potent agonist of this receptor (234). Indeed, we confirmed that LSS inhibitors 
induced the LXR target gene, ABCA1. However, we were unable to reproduce 
the anti-viral effect with the selective small molecule LXR agonist, GW3965. 
Furthermore, the LXR antagonist, GSK2033, failed to block that anti-viral effect 
of either LSS inhibitors or 24(S),25 EC. This led us to believe that the other 
known function of 24(S),25 EC, i.e. blocking the activation of the transcription 
factor sterol regulatory element-binding protein (SREBP), might be responsible 
for anti-viral effect. Further studies are required, for example using siRNA tar-
geting SREBP, to confirm this. 
 Given that the siRNA screen and the majority of our follow-up experiments 
were performed using the minor group serotype, RV2, it was necessary to gain 
confidence that LSS inhibitors would possess anti-viral activity against a broader 
range of RV serotypes. Accordingly, we confirmed anti-viral efficacy against the 
major group serotype, RV16. We chose to conduct those experiments in ALI cul-
tures, for two main reasons. First, we wanted to demonstrate the anti-viral activ-
ity of this mechanism in a more physiologically relevant model of infection. 
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Second, our previous experience told us that RV16 establishes a more robust in-
fection in ALI than it does in submerged NHBE cells. It would have been valua-
ble to have tested an RV-C strain in the ALI infection model but, at the time, we 
did not have the possibility do so. Confirming the findings of the siRNA screen, 
we failed to show any effect of the small molecule inhibitors on RSV replication 
in hep-2 cells (unpublished, data not shown).  
 Recent reports have suggested an interplay between type I IFN responses and 
the cholesterol biosynthetic pathway (235). It was found that cholesterol-25-hy-
droxylase (CH25H) is an ISG. CH25H catalyses the production of 25-hydroycho-
lesterol (25HC), which was shown to inhibit the growth of several viruses (235-
237). Subsequently, York et al showed more broadly that IFN signaling counter-
acts cholesterol biosynthesis and vice versa and went on to suggest a potential 
mechanism for this, via STING (stimulator of interferon genes) signaling in re-
sponse to cyclic GMP (238). This led us to hypothesise that perturbing choles-
terol synthesis via LSS could lead to an increase in the IFN response to RV. We 
confirmed this to be the case, with a 4-fold increase in IFNB mRNA in the pres-
ence of the LSS inhibitor BIBB-515. Although this might imply that enhance-
ment of the IFN response could explain the anti-viral effects that we have 
observed, we do not believe this to be the case. This is because the observed anti-
viral effect precedes the production of significant levels of IFN. Instead, we be-
lieve that LSS inhibition may in fact have a direct impact on viral replication as 
well as an ability to increase virus-induced IFN responses. 
Our discovery of the role of LSS adds to the increasing number of lipid regu-
lation and lipid metabolism components that are found to be essential for viral 
replication, such as PI4KIIIb, OSBP and LXR, which have been discussed ear-
lier. Clearly, the synthesis and localization of lipids and lipid membranes are 
likely crucial for virus propagation, throughout the replication cycle from entry 
to exit. Another important cellular process involving regulation of lipid mem-
branes is autophagy, and there is growing evidence that viruses can control this 
process to facilitate their own replication. For example, autophagy regulation has 
been shown to play a role in RV replication and also IFN responses (46, 145, 239, 
240). Further research is warranted to further investigate the precise role of au-
tophagy throughout the viral infection cycle. 
 Beyond LSS, we also interrogated further the output of the primary siRNA 
screen. For funding reasons, we were limited to advancing around 250 hit mRNA 
to Pass 2. However, this was only a proportion of the mRNA which passed the 
pre-defined hit criteria, based on either redundant siRNA activity (RSA) or a 
fold-change cut-off. We wanted to identify pathways and molecular functions 
which may be over-represented in the hits, and to have sufficient statistical 
power, we wanted to maximise the number of hits included. To do this, we used 
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a third statistical analysis method, by performing a t-test based on the mean 
value of the three siRNA molecules for each gene, adjusting for multiple testing 
using Benjamini-Hochberg. A total of 1129 mRNA passed at least one of the 3 
criteria, and we used this as the basis of the pathway enrichment analysis using 
Ingenuity Pathways Analysis (241). At the canonical pathway level, the most 
highly over-represented pathways included IL-1, nuclear factor (NF) B and IFN 
signaling. A central role of NFB was revealed, supporting a hijack hypothesis 
which has been reported in the literature (Figure 7) (242). At the molecular func-
tion level, the most highly over-represented were those involved in viral replica-
tion and apoptosis/survival (Figure 8). The latter finding gave further confidence 
that the screen was successful and identified genes of known importance to viral 
infection. 
Figure 7. Pathway enrichment analysis of the siRNA primary screen output. 
”NFkB activation by viruses” canonical pathway overlaid with mRNA present in the 1129 ”hit” list 
(green). Analysis was performed using Ingenuity Pathways Analysis. 
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Figure 8. Diseases and molecular functions represented by the 1129 hit mRNA from the siRNA 
primary screen. Analysis was performed using Ingenuity Pathways Analysis. 
4.2 The efficacy of on-demand inhaled IFN-1a 
for the prevention of severe asthma exacerbations 
(Paper II) 
 
Since Wark et al at the University of Southampton, UK, first reported evidence 
for deficient type I IFN responses in BEC from asthmatic patients in 2005, efforts 
began to develop inhaled recombinant IFN-1a (the same drug substance that 
had been licensed in the 1990s as a systemic therapy for the treatment of relaps-
ing/remitting multiple sclerosis), for the prevention of virus-triggered asthma ex-
acerbations (66, 120). This led to the formation of Synairgen Research Ltd., a 
biotech company which span out of the University of Southampton. Synairgen 
advanced inhaled IFN-1a to a phase 2 trial in asthmatics with a broad range of 
disease severity (British Thoracic Society (BTS) guidelines 1-5) (243). In that 
trial, asthmatics were given a 14-day course of nebulized IFN-1a or placebo fol-
lowing cold or flu symptoms. The primary endpoint was the 6-item asthma con-
trol questionnaire (ACQ-6). Although the primary endpoint was not met in the 
overall cohort, a planned subgroup analysis showed a significant benefit of 
IFN-1a in the patients with “difficult-to-treat” asthma, i.e. BTS 4-5 (119). 
 Following the results of Synairgen’s trial, inhaled IFN-1a was in-licensed 
by AstraZeneca for further development. Given that only a small subgroup 
showed efficacy in the previous trial, we set out to design a trial which would 
evaluate that patient subgroup with sufficient statistical power. The Interferon for 
Exacerbations of Asthma (INEXAS) trial therefore studied severe asthma pa-
Orange – Enhanced viral replication 
Blue    – Inhibited viral replication
Intensity of colours indicates level of effect
Larger box size reflects lower p-value 
Cell death and survival (p<0.05)*
1. Apoptosis
2. Cell death
3. Necrosis,
4. Cell viability
5. Cell survival
Infectious disease (p<0.05)*
6.  Replication of  virus,
7.  Replication of RNA virus
8.  Viral infection
9.  Replication of influenza virus
10. Infection by RNA virus
* Benjamini-Hochberg adjusted p value
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tients (GINA 4-5, similar to BTS 4-5), using a similar study design to the previ-
ous trial (243, 244). Due to medical need and commercial value, we chose severe 
exacerbations, instead of ACQ-6, to be the primary endpoint, and powered the 
study accordingly. 
The outcome of the primary endpoint was negative, although there was a ben-
eficial effect of IFN-1a on lung function. A detailed account and discussion of 
the trial and its results can be found in Paper II. Here, I will discuss further 
some of the findings related to the virus detection and biomarker analysis that 
were not covered in Paper II. 
Virus detection was performed retrospectively in nasal lavage and sputum 
samples collected during the first week of treatment. As outlined in Paper II, 
randomization to study drug was determined based on confirmed cold or flu 
symptoms. We elected not to utilize virus positivity as a randomization criterion 
because we believed based on previous findings that cold symptoms may be 
more sensitive that the virus test itself (12). Furthermore, waiting for a virus test 
result would have further delayed treatment start. We utilized a commercially 
available RT-PCR kit for the detection of 21 respiratory pathogens (FTD respira-
tory pathogens 21 kit). Overall, the percent of patients positive for any virus or 
RV was 54% or 17%, respectively. This is somewhat lower than expected when 
comparing to previous studies (10, 43, 119). Although RV was, as expected, the 
most common virus species detected, the proportion of all virus detections (19 of 
59, 32%) was particularly low (Figure 9). It is not known why this was the case 
although, as discussed below, it may relate to differences between participating 
countries in the viruses circulating at the time of conducting the trial. 
Figure 9. Subjects positive or negative for respiratory viruses in the INEXAS trial. 
A panel of 21 respiratory pathogens were detected by RT-PCR in nasal lavage and sputum samples, 
during the first week of the treatment period. A subject was regarded as virus or RV positive if there 
was a positive detection in any sample at any visit. 
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We also analysed virus positivity by visit and sample type. At randomization, 
virus positivity was lower in nasal lavage (30%) than in sputum (38%). The same 
trend was observed for RV positivity (6% in nasal lavage and 13% in sputum) 
(Figure 10). As mentioned in Section 3.4.1, lower detection rates in nasal sam-
ples compared to sputum have been observed previously. Further virus detection 
was performed in sputum at days 3 and 7 of the treatment period. As expected, 
virus positivity declined over time, with 51% at day 3 and 45% at day 4. The 
same was the case for RV positivity (17% at day 3 and 15% at day 4). There was 
no evidence for a difference between active and placebo at any time point, alt-
hough numbers were low. 
 
Figure 10. Subjects positive or negative for respiratory viruses at randomisation by sample type in 
the INEXAS trial. 
A panel of 21 respiratory pathogens were detected by RT-PCR in nasal lavage (left) and sputum 
(right) samples. Upper panel: any virus. Lower panel: RV. 
 
Positive
Negative
Any virus
RV
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We then compared virus positivity in patients with or without clinically con-
firmed colds based on the Jackson Cold Score (see ref (245, 246) and methods in 
Paper II). We hypothesized that patients with confirmed colds would be en-
riched for virus positivity. Indeed, when comparing patients who fulfilled both 
criteria for clinically confirmed colds with those who met neither, overall virus 
positivity was higher (59% vs 40%). However, no such trend was observed for 
RV (18% vs 20%) (Figure 11). 
Figure 11. Subjects positive or negative for respiratory viruses by clinical cold status in the 
INEXAS trial. 
A panel of 21 respiratory pathogens were detected by RT-PCR in nasal lavage and sputum samples. 
A subject was regarded as virus or RV positive if there was a positive detection in any sample at any 
visit. Upper panel: any virus. Lower panel: RV. Left panel: cold not confirmed by either Jackson or 
Predy methods (245, 246). Right panel: clinically confirmed cold by both Jackson and Predy meth-
ods.  
Further analysis of the virus detection results was performed by country (Fig-
ure 12). Of the 7 countries included in the trial, the 3 with highest virus detection 
rates were South Korea, Spain and Columbia (71%, 71% and 67%, respectively). 
The picture was somewhat different for RV, with France, Australia and Colum-
bia showing the highest RV detection rates (50%, 33% and 21%, respectively). It 
should be noted however that for France and Columbia, data were available for 
only 2 and 3 samples, respectively, with one sample in each country  
Positive
Negative
Jackson: N
Predy: N
Jackson: Y
Predy: Y
Any virus
RV
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Figure 12. Subjects positive or negative for respiratory viruses by country in the INEXAS trial.  
A panel of 21 respiratory pathogens were detected by RT-PCR in nasal lavage and sputum samples. 
A subject was regarded as virus or RV positive if there was a positive detection in any sample at any 
visit. Upper panel: any virus. Lower panel: RV. ARG: Argentina. AUS: Australia. COL: Columbia. 
ESP: Spain. FRA: France. GBR: United Kingdom. KOR: South Korea. 
being positive for RV. As a proportion of all viruses detected, RV differed sub-
stantially between countries, ranging from 13% in South Korea to 100% in 
France, Australia and Columbia. Interestingly, a large proportion of subjects 
were recruited in Argentina at a time when there was an ongoing flu epidemic.  
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Twenty-four (56%) subjects recruited in Argentina were virus positive, of which 
7 (29%) were RV positive. When it comes to flu, 4 (17%) were positive for either 
H1N1, influenza A or influenza B. This was by far the highest flu detection rate of 
any country, with only 3 other positive detections (Columbia, Spain and United 
Kingdom). 
In terms of virus species, the 3 most commonly detected viruses were RV 
(14% of samples), RSV (7%) and metapneumovirus (6%). Influenza was less 
commonly detected (3% for H1N1 and 1% for FluA and FluB, respectively). 
CXCL10 is a well-described marker of the IFN response and has been shown 
to be a robust biomarker of viral exacerbations (247-250). Hence, we utilized se-
rum CXCL10 as a biomarker to measure both the endogenous IFN response and 
the response to the drug. As described in Paper II, this enabled us to confirm 
pharmacodynamic activity of the drug as well as to compare subgroups based on 
the level of endogenous IFN response. Given the close relationship between 
CXCL10 and viral load and that in RV challenge studies, viral load correlates 
with symptoms (24, 248), we hypothesized that CXCL10 levels would have a re-
lationship to infection status, cold symptoms and asthma symptoms. We there-
fore subdivided subjects based on their CXCL10 level at the time of reporting 
symptoms, before the first dose of study drug. Surprisingly, we saw no relation-
ship between CXCL10 levels and any of the above parameters. We also evalu-
ated CXCL10 levels in those subjects with severe exacerbations and again, saw 
no difference compared to the overall study cohort. However, we did find one in-
teresting trend, in that the robustness of the CXCL10 response at randomisation 
differed markedly between countries. In Argentina, CXCL10 levels increased to 
the greatest extent, whilst in UK and South Korea, almost no increase in 
CXCL10 was observed (See Figure 13). We could not find any other clinical cor-
relate with this inter-country CXCL10 difference, although it is intriguing to 
speculate that this may relate to the higher rate of influenza infections in Argen-
tina. Indeed, although there were only 7 influenza positive subjects, the CXCL10 
level at randomization tended to be higher in those than in subjects positive for 
other viruses (not shown). 
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Figure 13. Serum CXCL10 levels from screening to randomisation by country in the INEXAS trial. 
CXCL10 was measured in serum samples using an MSD V-plex immunoassay. Levels are compared 
between Visit 1 (screening) and Visit 2 (randomisation visit, at time of cold/flu symptoms but before 
first dose of study drug) in subjects enrolled in Argentina (A), South Korea (B) or United Kingdom 
(C). p-value is determined using Kruskal-Wallis. 
We measured a panel of inflammatory biomarkers in serum at baseline, 
throughout the treatment period and at follow-up (3 days and 2 weeks after end-
of-treatment), and the majority of this analysis is described in Paper II. We in-
cluded the type-2 allergic inflammatory cytokines IL-4, IL-5 and IL-13 based on 
the evidence that there is a counteractivity between IFN signaling and type-2 in-
flammation, as discussed in Section 1.4.3. We hypothesized that inhaled IFN-1a 
would reduce IL-4, IL-5 and IL-13 levels in serum. Although we were unable to 
measure IL-4 and IL-5 in all but a few samples, we obtained sufficient IL-13 data 
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to perform a comparison of the active and placebo groups. At baseline and 
throughout the treatment, there were no differences in IL-13 levels between ac-
tive and placebo. However, at the 2-week follow-up visit, IL-13 levels were 
lower in the IFN-1a group compared to placebo (Figure 14). It is tempting to 
speculate that activation of the IFN response may have resulted in a switch of the 
immune response away from allergic type-2 inflammation, akin to what has been 
shown for agonists of the type I IFN-inducing receptors, TLR7 and TLR9 (124, 
251, 252). To test this hypothesis in allergic asthmatic patients, an inhaled TLR9 
agonist is currently being evaluated in the phase 2 trial (253). If the hypothesis is 
supported by this trial, inhaled IFN-1a could be another interesting approach to 
achieve the same goal. 
Figure 14. Serum IL-13 levels at 2 weeks post end of inhaled IFN-1a or placebo treatment. 
IL-13 was measured in serum samples using an MSD U-plex immunoassay. AZD9412: IFN-1a.  p-
value is determined using Kruskal-Wallis. 
One possible explanation for the lack of efficacy in the INEXAS trial is that 
starting treatment within 48 hours of cold symptoms is too late to prevent a 
worsening of asthma. This is supported by a recent trial of the RV capsid binder 
vapendavir and also the time courses of upper and lower respiratory tract symp-
tom scores in asthmatics following experimental RV challenge (27, 105). To get 
around this, other dosing regimens such as post-exposure or seasonal prophy-
laxis are worthy of exploration. However, when it comes to prophylaxis, further 
safety studies would be required to show tolerability to inhaled IFN-1a dosing 
over longer periods of time. Should the results of future tolerability studies im-
pose limits on dosing frequency, less frequent dosing (e.g. once per week) could 
be evaluated. However, the kinetics of the IFN response has not been explored 
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extensively enough to know what dosing intervals could be therapeutically via-
ble. We have recently shown that overnight treatment of macrophages with IFN 
is sufficient to induce ISGs, and protect cells from influenza infection, for up to 1 
week (unpublished observations). This provides evidence that once per week, 
prophylactic dosing could be a viable approach to evaluate the efficacy of in-
haled IFN-1a for the prevention of virus-triggered exacerbations. 
4.3 The role of viruses, bacteria and human beta 
defensin-2 in exacerbations of COPD  
(Papers III-IV) 
Infections are believed to be important drivers of COPD both in stable disease 
and at exacerbation. The importance of respiratory viral infections as exacerba-
tion triggers is well established. Different endotypes of exacerbation have been 
characterized based on the presence or absence of viral or bacterial pathogens, 
although the prevailing opinion in the field is that the viral infection is the initial 
trigger, which then precipitates an outgrowth of pathogenic bacteria in the lung. 
As discussed in Section 1.6.1, evidence from both experimental RV challenge 
and naturally occurring RV infections supports this (26, 168). 
 To address to some depth the role of different trigger factors in COPD exac-
erbations, we chose to perform a 2-year longitudinal observational study in a co-
hort of COPD patients in Guangzhou, China. The motivation for performing the 
study in China was based on several considerations. First, since air pollution is 
known to be an important driver of exacerbations in China, and Guangzhou is a 
large metropolitan area with high pollution levels (254), we had the possibility to 
study air pollution, and its interaction with viruses and bacteria, as a driver of ex-
acerbations. Second, China is a nation of strategic importance to AstraZeneca, 
both as a research base and as a major market for respiratory medicines. Third, 
similar exacerbation studies had been performed in European and North Ameri-
can cohorts, and the cohort at Guangzhou gave us the possibility to compare and 
contrast findings from those studies (249). Finally, Professors Nanshan Zhong 
and Rongchang Chen at the Guangzhou Institute for Respiratory Diseases are 
leading experts in COPD, with access to patients across the severity spectrum 
(many previous western cohort studies were enriched for frequent exacerbators 
and at Guangzhou, the cohort would be more representative of a real-world pop-
ulation). 
 The Guangzhou COPD study was completed over a 2.5-year period, with the 
first subject enrolled in mid-2010 and last subject, last visit in early 2013. The 
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overall exacerbation rate was 0.4 per year, with very little seasonal variation. 
This contrasts with previous studies which have shown a peak around Christmas 
time (21, 22). However, since the Christmas peak is believed to be precipitated 
by families gathering to celebrate, and Christmas is not a major celebration in 
China, it is not entirely surprising that such a peak was not observed in Guang-
zhou. The month of March showed a higher exacerbation rate in two of the three 
years. Following the completion of all patient visits, a biomarker plan was de-
vised to permit the investigation of biological endotypes associated with the clin-
ical, microbiological and environmental data that had already been gathered. A 
wide range of biomarkers were measured in sputum, serum and/or plasma and 
multivariate modelling of all data is ongoing.  
One such biomarker, hBD-2, became the central topic of Paper IV, due to its 
relevance to host defense against respiratory pathogens. Our hypothesis was that 
COPD patients have deficient immunity against pathogens, and previous litera-
ture on hBD-2 in COPD made this AMP an intriguing candidate (26, 67, 189, 
191, 192, 255, 256). We initially found that serum and sputum hBD-2 levels were 
not significantly different between COPD patients and control subjects. How-
ever, it was clear that some patients had lower levels of hBD-2 in sputum. We 
went on to show that the patients with lower sputum hBD-2 tended to be those 
who had at least 1 exacerbation during the 2-year observation period. Further 
analysis showed that low hBD-2 levels were associated with risk of exacerbation 
in following 12 months. We next hypothesized that low hBD-2 levels might asso-
ciate with the presence of sputum pathogenic bacteria during stable disease. 
However, no such association could be found, and neither was there any associa-
tion with respiratory viruses in the nose or sputum. Subsequently, we turned our 
attention to hBD-2 levels at exacerbation. We expected hBD-2 levels to increase 
at exacerbation, given that is it inducible following inflammatory signaling (257). 
However, although some patients showed an increase of hBD-2 from stable dis-
ease to exacerbation, others did not. When we compared pathogen status at exac-
erbation in patients with low or high hBD-2 levels at exacerbation, we found that 
patients with low hBD-2 were more often positive for a respiratory virus. This 
might suggest that respiratory viral infection somehow suppresses the hBD-2 re-
sponse, which may in turn render the airways more susceptible to outgrowth of 
pathogenic bacteria. For a summary of the viral and bacterial detection rates at 
stable disease and exacerbation, please refer to Paper IV.  
In agreement with the work of others, we showed that virus positive exacer-
bations were characterized by high levels of serum and sputum CXCL10, 
CXCL11 and IFN-γ (248-250). As discussed in Section 1.6.2, there is evidence for 
a relationship between IFN signaling and promotion of bacterial infections, lead-
ing us to speculate that the virus-induced IFN response could be one mechanism 
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by which hBD-2 levels are suppressed in the lungs of COPD patients at the time 
of exacerbation. This a topic worthy of further investigation. 
There are clear limitations to our findings. First, we only investigated a single 
AMP in Paper IV. We chose to study hBD-2 due to the fact that it is inducible 
(and therefore arguably more susceptible to dysregulation), it is exclusively ex-
pressed by epithelial cells, and there are reports of both genetic association with, 
and altered expression in, COPD. However, as discussed in Section 1.6.3, there 
are several families of AMPs which are expressed in the lung, and it would be of 
interest to investigate the association of those with exacerbations. For example, 
Mallia et al demonstrated reduced levels of SLPI and elafin following experi-
mental RV challenge in COPD patients (26). Another limitation is that our find-
ings are based on a single cohort. It would be important to replicate these 
findings in additional cohorts, in both China and other parts of the world.  
Additional analyses have been performed on the Guangzhou study which 
were beyond the scope of Paper IV. Daily air pollution levels (sulphur dioxide 
(SO2) and particulate matter of ≤10 µm in diameter (PM10)) were collected 
throughout the study. First, we investigated whether the time course of either 
pollutant was correlated with exacerbation rates. Although there was no overall 
correlation, we found that the highest monthly average level of PM10 occurred 
contemporaneously with the highest peak of exacerbation frequency, in March 
2012 (Figure 15). Furthermore, in a discrimator analysis for the prediction of ex-
acerbations, PM10 emerged as one of the strongest predictors (Figure 16) (250). 
A more detailed analysis of the 6-week period covering these peaks revealed 2 
weeks with increased exacerbation frequency, which were preceded by sharp in-
creases in PM10. A 1-week lag time between the PM10  increase and disease events 
is similar to what has been described previously (258, 259). There may be an in-
teraction between air pollution and other exacerbation risk factors such as viral 
infections (260-262). To this end, we investigated the correlation between PM10 
or SO2 and virus positive and virus-negative exacerbation rates separately. Intri-
guingly, we found a significant correlation between SO2 levels and virus-positive 
exacerbations (Figure 17). There are some reports which support a link between 
SO2 and innate immunity, but further mechanistic studies are warranted (263-
269). 
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Figure 15. The relationship between air pollution (PM10) and exacerbation frequency in the 
Guangzhou COPD cohort. 
Monthly maximum PM10 values (black line) and exacerbation frequencies (red line) expressed as 
proportion of the maximum observed value. 
 
 
. 
 
 
 
 
Figure 16. Factors which discriminate exacerbation months from exacerbation-free months in the 
Guangzhou COPD cohort. 
The following steps were repeated 1000 times for all available clinical and biomarker variables, each 
with the 161 exacerbation months (months in which a given patient had an exacerbation) and a new 
random set of 161 exacerbation-free months (months in which for a given patient, an exacerbation 
did not occur): 1. The most significant variables for discriminating between exacerbation months and 
exacerbation-free months were selected; 2. The selected variables from step 1 were assessed for their 
ability to correctly classify an exacerbation or an exacerbation-free month. The overall error rate for 
the classifications (using cross validation) was 29%. Shown in the graph are the 6 variables that cor-
rectly classified exacerbations vs. stable disease >50% of the time. (CXCL11 = CXC motif chemokine 
ligand 11; IL_1b = interleukin-1β; EXACT max cough, EXACT total = symptom scores derived from 
EXACT-PRO) 
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Figure 17. The relationship between air pollution (SO2) and exacerbation frequency in the Guang-
zhou COPD cohort. 
Monthly maximum SO2 values (black lines) and exacerbation frequencies (red lines) expressed as 
proportion of the maximum observed value. A: Virus negative exacerbations only; B: All exacerba-
tions; C: Virus positive exacerbations only; D: Correlation coefficient and p-value for the time pro-
file of SO2 levels versus exacerbation frequency. 
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5. Conclusions 
The main conclusions from this thesis are: 
 
Paper I 
Phenotypic functional genomics screening using RNAi can be used to success-
fully identify targets and pathways which can be modulated to affect RV replica-
tion in NHBE cells. 
Inhibition of LSS inhibits RV replication in primary NHBE cells via a mech-
anism which involves the induction of 24(S),25 EC but not LXR agonism. The 
anti-viral effect was observed against serotypes of both the major (RV16) and 
minor (RV2) groups, indicating broad spectrum anti-RV activity. In addition, we 
demonstrated that RV-induced IFNβ production is enhanced by LSS inhibition, 
suggesting that this mechanism has a dual role, inhibiting viral infection both di-
rectly and indirectly through promoting anti-viral host defense. Inhibition of LSS 
is thus a promising target for the prevention of RV-triggered exacerbations of 
asthma and COPD. 
 
Paper II 
When given following symptomatic colds or flu, inhaled IFNβ-1a was not able to 
prevent the occurrence of severe asthma exacerbations but did significantly im-
prove lung function. Reasons for the lack of effect on exacerbations may be in 
part due to the start of treatment being too late. Exploratory subgroup analysis 
suggested that patients with high blood eosinophils or low IL-18 relative change 
at treatment baseline, have the greatest improvement in lung function by IFNβ-
1a. Overall, the results suggest that inhaled IFNβ-1a could be a valuable therapy 
for the prevention of asthma worsening following viral infections, but that fur-
ther research into treatment regimen and responder populations is required to 
maximise the potential for treatment benefit. 
 
Papers III-IV 
COPD patients in China were successfully followed up for 2 years, with captur-
ing of exacerbations during that period. The results of the study support a rela-
tionship of exacerbations with viral and bacterial infections. Furthermore, 
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increased levels of the air pollutants, PM10 and SO2, are also associated with ex-
acerbations, with a potential interaction between SO2 and viral infections at exac-
erbation.   
Low levels of sputum hBD-2 in stable disease are associated with the future 
occurrence of exacerbations. At exacerbation, the presence of a respiratory virus 
is related to low levels of hBD-2. Finally, viral exacerbations are associated with 
increased levels of CXCL10, CXCL11 and IFNγ in serum and/or sputum, sup-
porting the results of previous studies. Overall, these findings suggest that COPD 
patients with impaired innate anti-microbial defense through low hBD-2 levels 
are at increased risk of exacerbation, especially in the context of an acute respir-
atory viral infection. Therapeutic approaches which boost hBD-2 levels in the 
airway may prove to be useful for the prevention of COPD exacerbations. 
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6. Future Perspectives 
Taken together, this thesis has identified factors which play an important role in 
the complex relationship between respiratory viruses and their human hosts in 
the development of exacerbations of asthma and COPD. A wide-ranging ap-
proach has been utilized in the research performed, from the mechanistic in vitro 
studies described in Paper I, through a randomized, placebo-controlled clinical 
trial in Paper II, to a longitudinal observational study of Papers III-IV. 
 Over the last 5-10 years, significant developments have been made in under-
standing host-Picornavirus interactions, with the discovery of how Picornaviri-
dae such as RV manipulate intracellular lipid structures such as the Golgi 
apparatus to facilitate viral replication. As discussed in Sections 1.5.2.3 and 4.1, 
several proteins involved in lipid metabolism have been described to be hijacked 
by Picornaviridae. However, our finding in Paper I that LSS could be one such 
component is novel.  
 In investigating the mechanism by which LSS inhibition exerts an anti-viral 
effect, we discovered that 24(S),25 EC is both induced by partial LSS inhibition 
and is anti-viral in its own right. One of the known effects of 24(S),25 EC is to 
stimulate LXR, which in turn drives cholesterol efflux through transporters such 
as ABCA1. Using either an LXR agonist or antagonist, we could exclude LXR 
agonism as the mechanism through which LSS inhibitors exert an anti-viral ef-
fect. The other known effects of 24(S),25 EC are to inactivate SREBP by seques-
tering it in the ER membrane, a transcription factor which drives the expression 
of multiple key components of cholesterol biosynthesis, and to directly inhibit 
HMG-CoA reductase (234). In Paper I, the role of those mechanisms has not 
been explored.  
The finding in Paper I that LSS inhibition leads to an enhancement of RV-
induced IFNβ production is consistent with another report by York et al suggest-
ing an inverse relationship between cholesterol biosynthesis and type I IFN re-
sponses (238). However, we have not investigated the mechanisms driving this 
IFNβ enhancement and whether the mechanism is similar to that described in the 
previous report by York et al. Our results do, however, suggest that induction of 
24(S),25 EC may be involved in the IFNβ enhancement and, given that York et 
al demonstrated the importance of ER components in their findings, it is intri-
guing to speculate that the actions of 24(S),25 EC at the ER membrane might 
lead to the same or similar mechanisms.  
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 As suggested above, further study on the role of LSS in RV replication 
should focus on the mechanism(s) by which 24(S),25 EC drives both the direct 
anti-viral effect and the IFNβ-enhancing effect, e.g. by investigating the effect of 
knocking down or knocking out SREBP or STING. Furthermore, the spectrum 
of RV species affected by this mechanism needs to be explored further, with par-
ticular attention paid to RV-C. Finally, the role of LSS and other recently-de-
scribed mechanisms of viral hijack, such as the PI4KIIIβ-induced re-organisation 
of the Golgi apparatus to form viral replication organelles, would be worthy of 
exploration. 
 In Paper II, we evaluated the efficacy of inhaled IFNβ, perhaps one of the 
best characterized components of anti-viral innate immunity, for the prevention 
of severe asthma exacerbations following symptomatic colds or flu. The lack of 
efficacy on severe exacerbations in the INEXAS trial does not in any way sug-
gest that IFNβ is not an important anti-viral defense protein, nor does it suggest 
that viral infections are not important triggers of exacerbations. On the contrary, 
it was clear that asthma worsening occurred following cold or flu symptoms, but 
the worsening may have peaked too soon for this therapeutic dosing regimen to 
successfully prevent it. The effect of IFNβ-1a on lung function was a promising 
finding, which suggests that with optimisation of treatment regimen, efficacy 
could be improved. Future study of inhaled IFNβ-1a in asthma should evaluate 
different treatment regimens, e.g. prophylaxis (year-round, seasonal or post-ex-
posure) vs therapeutic, for example utilizing the well-established experimental 
viral challenge models that are available.  
 The INEXAS trial was focused on asthma patients and it is possible that this 
mechanism may be efficacious for the prevention of COPD exacerbations. A trial 
in COPD similar in design to the INEXAS trial is currently in progress, and it 
will be intriguing to understand whether the same timing issues may apply in 
COPD patients, or if the longer duration and secondary bacterial infections 
which occur provide a greater window of opportunity for a efficacy (179). As dis-
cussed in Section 1.6.2, the relationship between type I IFN and risk of bacterial 
infections is somewhat unclear, especially in humans, and this trial may provide 
the opportunity to gain some understanding of how well the reported mouse in 
vivo studies translate to humans. 
 In an exploratory analysis, we found that patients with either high blood eo-
sinophils or low IL-18 relative change from screening, tended to exhibit the best 
lung function effect of inhaled IFNβ-1a. As discussed in Paper II, a biological 
rationale can be made for these subgroups, however further confirmation in 
larger, better-powered studies would be required before these subgroups can be 
regarded with any confidence as potential responder populations.  
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Whether or not the INEXAS trial cohort is a truly virus-susceptible population 
has been discussed in Paper II. There appeared to be no relationship between the 
magnitude of the endogenous IFN response (as measured by CXCL10 levels) 
and efficacy, and it is not known whether the patients studied were in any way 
“IFN deficient”. Patients were, however, required to have had a history of exac-
erbations related to upper respiratory tract infections. As mentioned in Section 
3.3.1, our recent epidemiological work in the West Sweden Asthma Study cohort 
has identified a potential “viral exacerbator phenotype”. Further profiling of pa-
tients exhibiting this phenotype is under way and might lead to improved meth-
ods for the identification of the patients most susceptible to viral exacerbations 
(and, in turn, perhaps more likely to respond to inhaled IFNβ-1a or other similar 
anti-viral therapies). 
On a technical note, a challenge in understanding the pharmacokinetic/phar-
macodynamic relationship in trials of IFNβ-1a is that the sensitivity of the cur-
rently-available assays is insufficient to permit reliable quantification of IFNβ. 
This means that a surrogate biomarker such as CXCL10 has to be used to assess 
drug response. Future development of inhaled IFNβ-1a would benefit from recent 
advancements in immunoassay technologies which provide sensitivity down to 
fg/ml concentrations. Increased sensitivity to detect IFNβ may also provide a 
method to identify “IFN-deficient” patients via blood sampling, something 
which is also currently not possible with the sensitivity of the currently-available 
assays. At the time of writing, no IFNβ assay has been commercialized using the 
more sensitive assay technologies, although efforts should be made to do this. 
 We have shown in our Chinese COPD cohort that low sputum hBD-2 levels 
are associated with risk of exacerbation. It could be that these findings are by 
chance, or alternatively are cohort- or region- specific. The results therefore need 
to be replicated in additional cohorts of frequent and infrequent exacerbators, to 
ensure that the finding is applicable across multiple cohorts and parts of the 
world. As discussed in Sections 1.6.3 and 4.3, hBD-2 is just one of many AMPs 
and the role of others should be explored further using samples from the Guang-
zhou and other similar studies and thus building on, for example, the findings of 
Mallia et al. 
Although we have identified a relationship between hBD-2 levels in sputum 
and a clinical outcome (i.e. exacerbation risk), the mechanism responsible for 
these low levels of hBD-2 have not been explored. For example, it is not known 
whether it is the induction of hBD-2 mRNA expression that is defective or alter-
natively some post-translational effect such as increased proteolytic cleavage. 
The latter seems likely since COPD lungs have been shown to have higher levels 
of proteases such as cathepsins and neutrophil elastase. Such proteases could be 
measured in the sputum to determine whether their levels correlate with hBD-2 
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measured in the same samples. A direct effect of NE and other proteases on 
cleaving hBD-2 could be investigated in vitro, e.g. using western blotting and 
bacterial infection assays to confirm effect on hBD-2 activity.  
It would be intriguing to investigate whether there is any relationship be-
tween the IFN response and hBD-2 levels. In Paper IV, we show that virus posi-
tive exacerbations are characterized both by low hBD-2 and high CXCL10, 
CXCL11 and IFNγ, but we have not shown whether hBD-2 levels and IFN re-
sponse biomarkers are mechanistically associated with one another. This could 
also be investigated in in vitro models of viral infection, or indeed viral/bacterial 
co-infection, using either submerged AEC or ALI cultures. Using such models, 
the relative roles of hBD-2 and IFN can be investigated by either measuring the 
endogenous response to viral/bacterial infections or by determining the effect of 
pre-treatment with exogenous hBD-2 on viral/bacterial host interactions. 
Paper III illustrates the breadth of data available from the Guangzhou COPD 
study, which permits extensive multivariate analysis of the different kinds of 
data obtained. Using such multivariate models in an unbiased way could allow 
the identification of the most important determinants of exacerbation risk. Pre-
liminary, as-yet unpublished multivariate analyses have shown that viral infec-
tions and PM10 are among the most important determinants of exacerbation risk. 
Of the soluble biomarkers measured in sputum and serum, sputum hBD-2 stands 
out as one of the strongest and interestingly does not correlate with any of the 
pro-inflammatory biomarkers measured (not shown). It will be extremely valua-
ble to complete these multivariate analyses and to confirm the preliminary find-
ings.  
When analyzing air pollutants (PM10 and SO2) over time, we see a relation-
ship with exacerbation frequency. More sophisticated modelling of the pollution 
data is planned in order to strengthen these findings. The relationship between 
SO2 levels and the frequency of virus-positive exacerbations is intriguing. In ad-
dition to confirming this finding with more sophisticated modelling, in vitro vi-
ral/bacterial infection models like the ones described above could be utilized to 
determine the effect of SO2 on virus/bacteria-host interactions. 
A common theme emerges through the somewhat diverse studies presented in 
this thesis: the IFN response is central, not only to the intricate intracellular vi-
rus-induced events that occur involving lipid shuttling and metabolism, but also 
to the downstream consequences of infection at the tissue and organ level, likely 
playing a key role in both anti-bacterial and anti-viral host defense. Despite the 
extraordinary complexity of the interaction between the virus and its host, this 
thesis demonstrates that key drivers of this interplay can be identified, manipu-
lated and, hopefully, developed into future medicines for the prevention of 
asthma and COPD exacerbations.  
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